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Background Information
Osteoporosis, or porous bone, is a disease characterized by low bone mass and
structural deterioration of bone tissue, leading to bone fragility and increased
susceptibility to fractures (Benhamou et al., 2001; World Health Organization, 1994).
This disease represents a major public health issue for 44 million Americans, 68% of
whom are women and 32% of whom are men (Black and Cooper, 2000). Although the
overall prevalence of fracture is higher in women, men generally have higher rate of
fracture-related mortality (Center et al., 1999). In the United States, 10 million
individuals have been diagnosed with osteoporosis and an additional 34 million have low
bone mass and are at increased risk of osteoporosis (National Osteoporosis Foundation,
2007). Osteoporosis is responsible for more than 1.5 million fractures annually in the
U.S., including 300,000 hip fractures, 700,000 vertebral fractures, 250,000 wrist
fractures, and more than 300,000 fractures at other sites (NIH, 2000). Estimated national
direct expenditures for osteoporosis-related fractures including hospitals and nursing
homes, are $14 billion each year (Black and Cooper, 2000; NIH, 2000). Osteoporosis is
most often associated with gonadal hormone deficiency (Gabet et al., 2005; Pacifici,
1996), unfavorable nutritional status (Holick, 2004), skeletal unloading (Smith et al.,
2002), ethanol consumption (Kabat et al., 1994), corticosteroid use (Adachi et al., 2001;
Hofbauer et al., 1999) or inflammatory conditions.
2Recently, the relationship between altered immune function and bone loss has
become a major topic of interest in effort to better understand the pathophysiology of
osteoporosis. Conditions associated with chronic elevation of pro-inflammatory
mediators have been implicated in the alterations in bone metabolism that negatively
impact bone mass and microarchitecture (Pacifici, 1996; Smith et al., 2006). Normally,
inflammation is a physiological response that protects against invading microorganisms
and infectious agents, and precedes tissue repair; however, dysregulation of the immune
response can lead to extensive tissue damage, disability, and death (Mehta et al., 1998).
Many human chronic inflammatory diseases are associated with sustained release of
inflammatory mediators. A significant body of literature has documented the relationship
between osteopenia or osteoporosis and inflammatory conditions such as human
immunodeficiency virus (HIV) (Mondy and Tebas, 2003; Paton et al., 1997), chronic
periodontitis (Van Dyke and Serhan, 2003), inflammatory bowel disease (Bernstein et al.,
2003), chronic pancreatitis (Haaber et al., 2000; Mann et al., 2003), rheumatoid arthritis
and lupus erythematosus (Romas et al., 2002; Uaratanawong et al., 2003). Furthermore,
evidence of estrogen’s anti-inflammatory properties has resulted in postmenopausal
osteoporosis being viewed as an age-related condition associated with alterations in
immune function (Pacifici, 1996).
Chronic elevation of pro-inflammatory mediators such as tumor necrosis factor
(TNF)-, interleukin (IL)-1, and prostaglandin E2 (PGE2) can disrupt normal bone
remodeling and ultimately lead to bone loss (Ishimi et al., 1990; Miyaura et al., 2003;
Romas et al., 2002; Sakuma et al., 2000; Tatakis, 1993). In general, these pro-
inflammatory mediators act both directly and indirectly to increase osteoclastogenesis,
3prevent osteoclast apoptosis (Johnson et al., 1989; Lorenzo et al., 1987), and/or inhibit
osteoblast activity (Wallach et al., 1993). The result of these alterations in bone
metabolism is an increase in the bone resorption by osteoclasts relative to the activity of
the bone forming osteoblasts.  
Stimulation of osteoclast differentiation and activity by these inflammatory
mediators appears to occur, at least in part, through enhanced expression of receptor
activator of nuclear factor-kappa B ligand (RANKL) by osteoblasts in the presence of
macrophage-colony stimulating factor (M-CSF). Upon initiation of the inflammatory
response, the osteoblast secretes RANKL which in turn binds to receptor activator of
nuclear factor-kappa B (RANK) on osteoclast precursor cells and initiates their
differentiation into osteoclasts. Both osteoclast differentiation and activity increase in
response to RANKL-RANK interaction (Khosla, 2001). The action of RANKL can be
inhibited by its decoy receptor, osteoprotegerin (OPG). OPG, a member of the TNF-
receptor family, is also expressed by osteoblasts and acts to inhibit bone resorption by
binding with strong affinity to RANKL, thereby preventing the RANKL-RANK
interaction (Hofbauer and Heufelder, 2001; Saidenberg-Kermanac'h et al., 2004). OPG
may also be pivotal in modulating inflammation mediated bone diseases (Bernstein et al.,
2005; Redlich et al., 2004; Saidenberg-Kermanac'h et al., 2004). Administration of OPG
attenuates bone loss and inhibits rheumatoid arthritis in TNF- transgenic mice (Redlich
et al., 2004). Therefore, regulation of this RANKL/OPG/RANK system may be one of
the key determinants of balance between bone formation and bone resorption under
inflammatory conditions. The interrelationship between bone metabolism and the innate
immune response likely explains why medical conditions typified by chronic elevation of
4pro-inflammatory mediators are associated with bone loss characterized by decreased
bone mineral density (BMD) and deterioration of trabecular bone microarchitecture
(Mondy and Tebas, 2003; Romas et al., 2002; Serrano et al., 1995).
While several FDA-approved pharmacological treatments for osteoporosis are
available, side-effects of these drugs remain an important consideration. For example, the
anti-resorptive agent, alendronate, reduces fracture of the spine and hip by approximately
50% in clinical trials (Liberman et al., 1996; Liedholm and Linne, 1996; McGrath, 1996);
however, bisphosphonates such as alendronate are poorly absorbed and the large doses
required which result in gastrointestinal (GI) complications for many individuals. In
addition to the GI complications, long-term use of bisphosphonates has recently been
linked to osteonecrosis of the jaw (Rodan and Martin, 2000). Recommending long term
use of other anti-resorptive agents, such as hormone replacement therapy (HRT) and
selective androgen receptor modulators (SARM) (Hanada et al., 2003; Rosen J, 2002) is
controversial due to the uncertainty of their efficacy and potential to increase the risk of
certain cancers (Cappon et al., 2004; Delmas et al., 1997; Rodan and Martin, 2000; Terry
et al., 2004). Intermittent parathyroid hormone (PTH) treatment is currently the only
FDA-approved anabolic agent that can restore bone mass for individuals with established
osteoporosis (Kroll, 2000; Rattanakul et al., 2003). Although this treatment provides the
first therapeutic option for people with significant bone loss, it is not a reasonable
treatment for many osteoporosis patients due to the cost of the drug, the inconvenience of
daily injections, the uncertainty of long-term treatment, and the risk of side-effects
(Hodsman et al., 2005). Ideally, it would be beneficial to offer natural therapies that could
be easily incorporated into the diet, which would reduce the risk of osteoporosis or could
5even be combined with pharmacological therapies to treat established osteoporosis.
Previous epidemiological studies have shown that consumption of legumes, fruits,
and vegetables (Muhlbauer et al., 2003; New et al., 2000), rich in phenolic compounds
and their derivatives (Hegarty et al., 2000; Johnell O, 2005), reduce the incidence of
osteoporosis. Diets high in fruits and vegetables have been linked to an increase in bone
accrual in boys aged 8-20 y (Vatanparast et al., 2005a) as well as a reduction in the rate
of bone loss in premenopausal women (Macdonald et al., 2005) and aging men (Tucker et
al., 2002). Consumption of beverages containing polyphenols such as green tea has been
associated with increased BMD (Wu et al., 2002). In addition, polyphenolic compounds
and their derivatives, which have antioxidant and anti-inflammatory properties, have been
shown to inhibit osteoclast differentiation and activity (Muhlbauer et al., 2003; Woo et
al., 2004), directly stimulate osteoblasts, and favorably alter bone formation markers
(Horcajada-Molteni et al., 2000; Mizutani et al., 1998).
Dried plums (Prunus domestica L.) are a rich source of polyphenols (1100-2600
mg/kg) and a number of micronutrients (e.g. vitamin K, potassium and boron) involved in
bone metabolism (Fang et al., 2002; Hollman and Katan, 1999; Nakatani et al., 2000).
The polyphenol content of this fruit contributes to its high oxygen radical absorbance
capacity rating (ORAC rating), resulting in the highest ORAC score among the most
commonly consumed fruits and vegetables (Kayano et al., 2004). A short-term study of
postmenopausal women consuming approximately 100 g of dried plum per day (i.e. 10-
12 dried plums) demonstrated that dried plum may enhance bone formation as indicated
by increased serum bone-specific alkaline phosphatase (ALP) and insulin-like growth
factor (IGF)-I (Arjmandi et al., 2002). Studies utilizing female animal models of
6osteopenia indicated that diets supplemented with dried plum could not only prevent
(Arjmandi et al., 2001), but also reverse (Deyhim et al., 2005) bone loss due to ovarian
hormone deficiency. Recent studies evaluating bone recovery following skeletal
unloading demonstrated that dried plum had comparable effects to intermittent PTH
therapy and that the polyphenols in dried plum may account for most of these effects
(unpublished data).
Muhlbauer and colleagues (Muhlbauer et al., 2003) were the first to demonstrate
that in male rats dried plum strongly inhibited bone resorption compared to other fruits
and vegetables. Our recent report (Franklin et al., 2006) showed that the bone protective
effects of dried plum on BMD and trabecular bone microarchitecture in gonadal hormone
deficient male animals were even greater than those observed in females. Dietary
supplementation with dried plum prevented the orchidectomy-induced decrease in bone
mass and mechanical strength which was accompanied by improved bone
microarchitecture. Circulating biochemical markers of bone metabolism and local gene
expression data suggested the improved bone quality resulted from increased bone
formation and decreased bone resorption, which was mediated by the IGF-I and RANK
pathways, respectively.
In gonadal hormone deficiency, TNF- is considered one of the predominant pro-
inflammatory mediators of bone loss (Cenci et al., 2000). TNF- inhibits osteoblast
activity and bone mineralization by down-regulating IGF-I (Gilbert et al., 2000) and ALP
(Pischon et al., 2004), and suppresses the expression of transcription factors, Osterix (Lu
et al., 2006) and Runx2 (Gilbert et al., 2002). Under conditions of gonadal hormone
deficiency, decreased osteoblast activity and promotion of osteoclast differentiation by
7inflammatory cytokines such as TNF- are associated with a defective antioxidant system
(Pacifici, 1996). Therefore, dried plum’s polyphenols may mediate its bone protective
effects by down-regulating the production of inflammatory mediators involved in
osteoclastogenesis and osteoclast activity as well as by altering osteoblast signaling and
function.
Research Objectives and Hypotheses
The purpose of this research project is to further our understanding of the
molecular and cellular mechanisms by which dried plum and its polyphenols improve
bone mass and microarchitecture. To accomplish this purpose, in vivo and in vitro studies
have been designed to address the following objectives.
Study 1
Nine-month-old orchidectomized (ORX) osteopenic rats will be randomly
assigned to either control or a dried plum supplemented diet (i.e. 25% w/w) to investigate
the ability of dried plum to reverse gonadal hormone deficiency-induced deterioration in
bone mass and microarchitecture after bone loss has occurred in ORX males. The
anabolic effects of dried plum will be compared to those of PTH.
Objective 1: To determine if dietary supplementation with dried plum can restore bone
mass (BMD) and bone mineral content (BMC) in gonadal hormone deficient osteopenic
male rats and to compare the degree of restoration to that of PTH.
Objective 2: To investigate whether dietary supplementation with dried plum can reverse
8the deterioration in microarchitecture of trabecular and cortical bone in osteopenic male
rats and to compare its effects to PTH.
Hypothesis 1: Dried plum supplementation will restore bone density and trabecular bone
microarchitecture in osteopenic gonadal hormone-deficient male rats and these effects
will be similar to the anabolic agent, PTH.
Objective 3: To evaluate the extent to which dried plum alters biochemical markers of
bone formation and resorption by assessing serum ALP and urinary deoxypyridinoline
(Dpd) and calcium excretion in osteopenic male rats. The alterations in biochemical
markers will be compared to the positive control, PTH.
Hypothesis 2: Osteopenic orchidectomized male rats consuming the dried plum
supplemented diet will experience an increase in serum ALP, but a decrease in urinary
Dpd and calcium excretion. The alterations in ALP will be similar to the effects of PTH,
but the decrease in bone resorption indicators will not mimic PTH.
Study 2
RAW 264.7 bone marrow macrophages will be used to evaluate the ability of
dried plum polyphenols to down-regulate inflammatory mediators and inhibit osteoclast
differentiation and activity under inflammatory and oxidative stress conditions. 
Inflammation will be induced by stimulating cells with lipopolysaccharide (LPS) while
oxidative stress will be induced by stimulation with hydrogen peroxide (H2O2). The
effects of the polyphenol extracts will be assessed on macrophages (i.e. no RANKL
added to the culture) and during osteoclastogenesis (i.e. RANKL added over 5 days).
9Objective 4: To determine whether the dried plum polyphenols decrease the
inflammation- and oxidative stress-induced osteoclast differentiation and activity by
examining the TRAP-positive, multinucleated osteoclasts and resorption pit formation.
Hypothesis 3: Dried plum polyphenols will decrease osteoclast differentiation and activity under
inflammatory and oxidative stress conditions.
Objective 5: To evaluate the ability of dried plum polyphenols to down-regulate the
production of inflammatory mediators (i.e. nitric oxide and TNF-) and key enzymes
(cyclooxygenase-2, COX-2 and inducible nitric oxide synthase, iNOS) regulating the
production of inflammatory mediators that promote osteoclastogenesis under
inflammatory and oxidative stress conditions.
Hypothesis 4: Dried plum polyphenols will decrease the production of inflammatory
mediators by murine macrophages and osteoclasts induced by inflammation and
oxidation.
Study 3
MC3T3-E1 pre-osteoblast cells will be used to evaluate the effects of dried plum
polyphenols on osteoblast activity and function under normal and inflammatory
conditions. TNF- will be used to induce the inflammatory response in osteoblasts.
Alterations in osteoblast gene expression of transcription and growth factors and
cytokines will also be assessed.
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Objective 6: To determine whether dried plum polyphenols increase osteoblast activity
and function under normal and TNF--induced inflammatory conditions by investigating
the intra- and extra-cellular ALP activity and mineralized nodule formation.
Hypothesis 5: Dried plum polyphenols will up-regulate ALP activity and mineralized
nodule formation in osteoblast cells under both normal and inflammatory conditions.
Objective 7: To determine whether the dried plum polyphenols will alter osteoblast gene
expression of key transcription factors (i.e. Runx2 and Osterix) and growth factors (i.e.
IGF-I) in the presence or absence of TNF-.
Hypothesis 6: Dried plum polyphenols will increase the gene expression of Runx2,
Osterix and IGF-I under normal and inflammatory conditions.
Objective 8: To determine whether the dried plum polyphenols will alter the gene
expression of RANKL and OPG in the presence or absence of TNF-.
Hypothesis 7: Dried plum polyphenols will decrease the RANKL expression without
altering the expression of OPG under normal and inflammatory conditions.
Limitations
The dose of dried plum (25%, w/w) incorporated into the animal diet in Study 1
may be considered quite high if attempts are made to extrapolate this dose to the human
diet. The intent of this study was not to be a dose-seeking experiment, but rather to
compare dried plum’s effects on the restoration of bone mass, microarchitecture and
metabolism with those of the potent anabolic agent, PTH. Previous studies have shown
11
that 25% is the most efficacious dose of dried plum (Franklin et al., 2006) and is well-
tolerated by rodents without any GI side-effect, such as diarrhea and vomiting
(unpublished observation). Hence in order to optimize the effects of dried plum in
comparison to PTH to better understand its mechanism of action, this high dose of dried
plum was utilized.
Another potential limitation to the in vivo study is related to the use of the ORX
rat model of osteoporosis. Although gonadal hormone deficiency-induced bone loss
occurs relatively abruptly in females during the early postmenopausal years, age-related
changes in gonadal hormone deficiency in males tend to be more gradual and extend over
the course of decades in the human lifespan. Therefore, some have suggested that the
ORX rat model may not represent bone loss associated with aging in males. However,
one may argue that treatments that are efficacious in the ORX male model, which
represents an exaggerated response, are likely to be even more effective when applied to
osteoporosis in men.
In the in vitro studies one of the possible limitations is that the polyphenols that
were tested were extracted from dried plum. As is the case of any extract, this does not
represent a purified mix of the polyphenols found in plums. A significant amount of
sugar and other nutrient and non-nutrient components may remain. Even though these
components may potentially confound treatment effects, the data in this study show
similar effects in terms of down-regulating inflammatory mediators, decreasing osteoclast
differentiation and increasing osteoblast activity as other phenolic compounds reported in
the literature (Chen et al., 2001; Mizutani et al., 1998; Wattel et al., 2003). Attempts to
further purify the polyphenols to remove other compounds, especially the remaining
12
carbohydrates, has resulted in conformational changes that alter the polyphenol’s
structure (unpublished observation). Studies using the available synthetic version of the
phenolic compound in dried plum or proportionate formulations of those found in the
fruit are warranted. Such studies would provide the opportunity to clarify the effects of
the polyphenols on osteoclasts and osteoblasts, and to address whether the effects
reported here are the results of individual compounds or the action of the polyphenols as
a whole. However, the problem with this approach is that neochlorogenic acid, the
predominant polyphenol in dried plums is very difficult to synthesize and synthetic
versions are not currently available.
In addition to issues regarding composition of polyphenols, relatively little is
known about the alterations in these compounds’ chemical structure during their
absorption and metabolism. Further in vivo studies are needed to identify the phenolic
compounds that appear in the serum and in tissues such as bone as well as their impact on
antioxidant systems and immune function.
Format of Dissertation
The three experiments included in the dissertation are organized as individual
manuscripts and written using the guide for instruction for authors from Osteoporosis
International, Bone and Calcified Tissue International, respectively. Additional data
and/or information that were not included in the manuscripts have been included in the
appendix.
13
CHAPTER II
REVIEW OF LITERATURE
Osteoporosis and Prevalence
Osteoporosis is a disease characterized by low bone mass and structural
deterioration of bone tissue, leading to bone fragility and increased susceptibility to
fractures (Kopera, 1989). Osteoporosis is a major public health threat for 44 million
Americans, 68% are women and 32% men (Black and Cooper, 2000). Although the
overall prevalence of fracture is higher in women, men generally have higher rates of
fracture-related mortality (Center et al., 1999). In the United States, 10 million
individuals have been diagnosed with osteoporosis and more than 34 millions have low
bone mass or osteopenia and are at increased risk for this disease. The number of older
adults (i.e. over 65 years) has increased dramatically during the last few decades and is
expected to continue to increase over the next 50 years (Black and Cooper, 2000). Today,
it is estimated that worldwide more than 495 million individuals are 65 years of age and
older, and this number is expected to increase to about 1,574 million by the year 2050
(U.S. Census Bureau, 2007). These demographic changes are likely to result in increased
incidence of hip fractures from 1.66 million in 1990 to 6.26 million in 2050. It is
estimated that approximately one-half of all hip fractures occurring in elderly people in
14
1990 occurred in Europe and North America; however, in view of the growth of the aging
Asian population it is expected that by 2050 greater than 50% of all hip fracture will
occur in Asia (Christodoulou and Cooper, 2003). 
In the U.S., osteoporosis is responsible for more than 1.5 million fractures
annually, including 300,000 hip fractures, 700,000 vertebral fractures, 250,000 wrist
fractures, and more than 300,000 fractures at other sites (Black and Cooper, 2000; NIH,
2000a). In those who recover from the fracture, more than half of the patients have
permanently impaired mobility (Cooper et al., 1993). Estimated direct expenditures in the
U.S. (i.e. hospitals and nursing home) for osteoporosis and related fracture are $14 billion
each year (Cummings, 1998), and the financial and health-related costs of osteoporosis
are expected to rise in future generations (Ben et al., 2001; Reeve et al., 2003).
Risk Factors for Osteoporosis
Osteoporosis is most often associated with low BMD occurring in response to
gonadal hormone deficiency (Gabet et al., 2005; Pacifici, 1996), skeletal unloading
(Smith et al., 2002), unfavorable nutritional status (Holick, 2004), ethanol consumption
(Kabat et al., 1994), corticosteroid use (Adachi et al., 2001; Hofbauer et al., 1999a), or
inflammatory disease.
Aging as well as adverse environmental factors may lead to decreased serum
estrogen and hypogonadism which is associated with low BMD in both females and
males (Bilezikian et al., 1998; Dopp et al., 1999; Genant et al., 1989). Premature
menopause, especially before the age of 45, is a strong determinant of bone loss and
increased risk of fracture among women (Christodoulou and Cooper, 2003). Recent
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studies suggested that estrogen has anti-inflammatory properties and contributes to the
inhibition of osteoclast function as shown by increased bone resorption activity observed
with diminished estrogen levels in both males and females (Cenci et al., 2000).
Physical loading and mechanical stress are known to increase BMD and certain
forms of weight-bearing exercise may retard bone loss (Bikle et al., 2003; Smith et al.,
2002). Reduced physical activity or immobilizations have negative effects on the skeleton
as evidenced by the significant reduction in bone mass observed with prolonged bed rest
(Palle et al., 1992). Similar degrees of bone loss have also been reported in the
microgravity environment of space (Carmeliet et al., 2001; Vico et al., 2000). Moreover,
epidemiological studies have shown that a relationship exists between physical inactivity
in the elderly and the risk of hip and vertebral fracture (Ammann and Rizzoli, 2003;
Arden et al., 1999; Argani et al., 2001). Although some of this effect might be due to the
increased risk of falling, the importance of physical activity on skeletal health throughout
the lifespan is well-documented (Karinkanta et al., 2005; Perrault, 2006).
Many nutrients have received attention regarding their role in bone health. A
meta-analysis by Cummings and Nevitt (1997) showed a positive association between
calcium intake and bone mass in pre-menopausal women. In middle-aged and elderly
women a positive association has been reported between 25-hydroxyvitamin D
concentrations and BMD (Nieves, 2003). Additionally, adequate vitamin D status in the
elderly may not only influence calcium homeostasis relative to bone, but also improve
muscle strength and reduce the risk and consequences of falls (Christodoulou and
Cooper, 2003). Other nutrients such as potassium (Macdonald et al., 2005), vitamin K
(Booth and Meyer, 1997; Vermeer et al., 1992), fluoride, copper (Rucker et al., 1975;
16
Smith et al., 2002; Strause et al., 1987; Teague and Carpenter, 1951), and vitamin C
(Leveille et al., 1997; Morton et al., 2001) are also associated with osteoporotic risk.
These nutrients are involved in acid-base balance (Macdonald et al., 2005), synthesis of
bone matrix, and serve as cofactors for protein synthesis (Rucker et al., 1975; Smith et
al., 2002; Strause et al., 1987; Teague and Carpenter, 1951), which are all required for the
bone remodeling processes. However, the influence of nutritional status on osteoporotic
or fracture risk is often very difficult to interpret (Buckley et al., 1996). This difficulty is
due to factors such as compromised absorption and metabolic activity of nutrients
associated with conditions such as gonadal hormone deficiency, disease states, and
physical inactivity.
Another risk factor for osteoporosis is the consumption of large quantities of
alcohol. The influence of excessive alcohol may be due to adverse effects on protein and
calcium metabolism, compromised mobility, depressed gonadal function, and toxic
effects on osteoblasts (Hefferan et al., 2003; Sampson, 2002). Long-term alcohol
consumption can interfere with bone growth and normal bone remodeling, resulting in
decreased BMD and increased risk of fracture (Williams et al., 2005). These effects may
be exerted directly or indirectly through cellular activity, hormones, and growth factors
that regulate bone metabolism (Callaci et al., 2004; Turner and Sibonga, 2001). Alcohol
consumption during adolescence reduces peak bone mass and can result in relatively
weak adult bones that are more susceptible to fracture (Ackard and Neumark-Sztainer,
2001). In adults, high levels of alcohol consumption (i.e. alcohol abuse) can disrupt the
balance between bone resorption and bone formation activity (Schnitzler et al., 2005);
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however, some evidence suggests that moderate consumption may decrease the risk of
fracture in postmenopausal women (De Lorimier, 2000; Macdonald et al., 2004).
In addition to alcohol, an inverse relationship between smoking and BMD has
also been reported (Broussard and Magnus, 2004; Gerdhem and Obrant, 2002; Hildebolt
et al., 2000). Meta-analysis has demonstrated that although there was no significant
difference in BMD between smokers and non-smokers at age 50; BMD in women was
diminished by 2% more in smokers than in non-smokers for each 10 years of age after
50; and the difference between the two groups was 6% at age 80 years (Law and
Hackshaw, 1997). These data suggest that smoking, especially in older women may
increase the rate of bone loss. Moreover, an independent effect of cigarette smoking on
the risk of hip fracture has been suggested by epidemiological studies (Cummings et al.,
1995).
Corticosteroids are widely used therapeutic agents for the treatment of
inflammatory diseases. Long-term corticosteroid use has been associated with the
development of osteoporosis (Joseph, 1994). Osteoporosis has been reported to occur in
up to 50% of persons who require long-term corticosteroid therapy and the risk of
vertebral fractures increased by 5-fold while the risk for nonvertebral fractures increased
by 2-fold (Lane and Lukert, 1998). The association between osteoporosis and
corticosteroids has been identified since they were first used in humans and evidence has
accumulated demonstrating that corticosteroids affect bone through multiple pathways
(Kim et al., 2006). The primary action of corticosteroids on bone appears to be related to
the direct inhibition of bone formation by osteoblasts and to a lesser extent, enhanced
bone resorption by osteoclasts. Impaired calcium absorption and increased urinary
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calcium loss leading to hyperparathyroidism have also been implicated as having a role in
these detrimental corticosteroid-elicited effects on bone biology (Canalis, 1996).
Other risk factors for osteoporosis include a variety of endocrine disorders such as
hyperparathyroidism, Cushing’s syndrome (Ohmori et al., 2003), malignant disease (e.g.
myeloma, lymphoma) (Atoyebi et al., 2002), and chronic renal failure (Cunningham et
al., 2004). Additionally, there is evidence that osteopenia and osteoporosis are closely
related to chronic inflammatory diseases (Hassoun et al., 1997; Romas et al., 2002;
Uaratanawong et al., 2003; Van Dyke and Serhan, 2003). Importantly, immune response
mediators known to be involved in chronic inflammatory diseases have been shown to be
intimately involved in bone metabolism and induce bone loss by increasing bone
resorption and decreasing bone formation (Pischon et al., 2004). Although therapeutic
agents commonly used in the treatment of these conditions such as glucocorticoids
(Adachi, 2001; McLaughlin et al., 2002) or highly active antiretroviral therapy (HAART)
(McDermott et al., 2001; Pan et al., 2004) can accelerate the rate of bone loss, osteopenia
also develops independent of treatment and may be mediated via host responses to the
underlying medical conditions (Van Dyke and Serhan, 2003).
Bone Loss in Inflammatory Conditions
Inflammation is a normal physiological response that protects the host from
invading microorganism and infectious agents, and precedes tissue repair (Cotran, 1999).
Dysregulation of the immune response, however, can lead to extensive tissue damage,
disability and death. Bone loss is a common clinical complication that presents in a
variety of diseases associated with chronic elevation of pro-inflammatory mediators. For
19
example, periodontal disease, characterized by gingival inflammation and alveolar bone
resorption resulting from primarily gram-negative bacteria, causes destruction of bone
and the collagen that support the teeth (Van Dyke and Serhan, 2003; WactawskiWende et
al., 1996). Osteopenia has been reported in 67-71% of patients infected with human
immunodeficiency virus (HIV) and another 13-21% of HIV-infected patient are
osteoporotic (Amiel et al., 2004; Landonio et al., 2004; Moore et al., 2001; Paton et al.,
1997). Although the etiology of HIV-associated osteopenia is unclear, elevated
proinflammatory cytokines and 1,25-dihydroxyvitamin D insufficiency are likely
contributors (Bruera et al., 2003; Carr et al., 2001; Huang et al., 2001; Jain and Lenhard,
2002; Mondy and Tebas, 2003). Perhaps the most common immune-related diseases
associated with bone loss are the autoimmune diseases. Rheumatoid arthritis, systemic
lupus erythematosus (SLE), multiple sclerosis (MS) and inflammatory bowel disease
(IBD) present with a number of factors that may have detrimental effects on bone
including, but not limited to, chronic inflammatory arthritis, reduced physical activity,
cytokine-promoted bone resorption, renal impairment, vitamin D insufficiency and
glucocorticoid use (Di Munno et al., 2004). Furthermore, there is increasing evidence of
estrogen’s role in immune function which has resulted in postmenopausal osteoporosis
being viewed as an age-related condition associated with alterations in immune function
(Pacifici, 1996).
Bone Remodeling Unit and Primary Regulators
Bone is a mineralized tissue that has both multiple mechanical and metabolic
functions and is continually remodeled by the action of osteoblasts and osteoclasts
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(Manolagas, 2000). Bone remodeling is a complex process involving a number of cellular
functions directed at coordinated resorption and formation of new bone (Manolagas,
2000). Bone mass is preserved by a tight balance between these two processes with
remodeling occurring at discrete locations known as basic multicellular units. Osteoblasts
are bone forming cells derived from mesenchymal stem cells that differentiate into a pre-
osteoblastic stromal cells and eventually into osteoblasts (Kartsogiannis and Ng, 2004).
Several molecules are associated with the osteoblast’s function which includes the
deposition and maintenance of mineralized skeletal structure. For instance, once matrix
synthesis begins in osteoblast cultures, the cells differentiate as genes encoding for ALP,
type I collagen (COL-I), and osteocalcin (OCN) are activated. Osteoblasts eventually
become embedded in the extracellular matrix consisting mainly of collagen fibrils and
matrix mineralization begins as mineral deposits extend along and within the collagen
fibrils (Kartsogiannis and Ng, 2004; Sudo et al., 1983).
Osteoclasts are large multinucleated cells derived from the hematopoietic
progenitors of the monocyte-macrophage lineage. These cells have the capacity to resorb
mineralized tissue due to their polarized morphology and ability to adjoin the calcified
matrix to form a ruffled border in resorption (Roodman, 1999). Bone resorption is
initiated by the attachment of osteoclasts to the target matrix and demineralization
involves acidification of the extracellular microenvironment, a process mediated by a
vacuolar H+-adenosine triphosphate (H+-ATPase) (Mattsson et al., 1994; Silver et al.,
1988). Acidic conditions mobilize the bone mineral and the demineralized organic
component is degraded by a lysosomal protease, cathepsin K (Gowen et al., 1999; Li et
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al., 1999). The products of bone degradation are endocytosed by osteoclasts, transported
to and released at the cell’s anti-resorptive surface (Nesbitt and Horton, 1997).
At any given time the skeleton has approximately a million basic multicellular
units in various stages of the remodeling sequence: 1) initiation and organization of the
basic multicelluar units, 2) activation of osteoclasts, 3) resorption of old bone, 4)
recruitment of osteoblasts, 5) formation of new bone or osteoid, and 5) mineralization
(Mundy GR, 1999). Bone remodeling is regulated by systemic hormones and local
factors, which influence proliferation, differentiation, recruitment and activation of
osteoclasts and osteoblasts (Abbas et al., 2003; Kikuchi et al., 2001b; Zhao et al., 2002).
These local factors, synthesized by osteoblasts and osteoclasts, include growth factors,
cytokines and prostaglandins. Abnormalities in any of these factors in favor of up-
regulating osteoclasts activity may lead to pathological bone resorption as seen in
inflammatory conditions and/or gonadal hormone deficiency (Jones et al., 2002; Rifas et
al., 2003; Roodman, 1999).
Gonadal Hormone Deficiency and Bone Loss
Estrogen deficiency in males and females is one of the most frequent cause of
osteoporosis and insufficient skeletal development (Ensrud et al., 1995; Jennings et al.,
1998). In both men and women, there is a steady decline in unbound estrogen levels with
aging, exacerbated in women at menopause by a marked decrease in estrogen levels
(Drake et al., 2003; Nelson et al., 2002). Although in men there is no abrupt cessation of
gonadal function, they do experience an age-related decrease in unbound sex steroids (i.e.
testosterone) resulting from progressive increases in circulating sex-hormone-binding
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globulin (Riggs et al., 2002). Decreased serum testosterone results in the reduction of the
aromatization of testosterone to estradiol (Howell and Shalet, 2001) or a direct effect on
osteoblast and osteoclast activity (Francis, 1999) which ultimately leads to bone loss
(Falahati-Nini et al., 2000; Isaia et al., 1992).
The term postmenopausal osteoporosis was first defined by Albright and
colleagues in 1941 (Albright and Reifenstein, 1941) and much of the initial research
focused on the role of estrogen deficiency in calcium balance (Heaney, 2001; Rosen et
al., 1997). Because estrogen is involved in the regulation of serum calcium, estrogen
deficiency leads to a slight elevation of plasma calcium, hypercalciuria and an overall
negative calcium balance (Gallagher et al., 1980). Recently, attention has shifted toward
the role of estrogen in the activation of the estrogen receptor (Grundberg et al., 2003)
and/or inflammatory cytokines (Roden et al., 2004; Safadi et al., 2000). Osteoblasts and
osteoclasts express functional estrogen receptors which bind to transcription factor such
as nuclear factor kappa-B (NF-B) (Orwoll et al., 1991). When estrogen receptors are
activated, they can prevent the binding of NF-B to promoter sites of cytokines such as
IL-6 and IL-1, and block the synthesis of these cytokines (Stein and Yang, 1995). Studies
(Cenci et al., 2000; Ryan and Nicklas, 2004) have shown that estrogen is involved in the
anti-inflammatory processes due to the up-regulation of pro-inflammatory cytokines such
as TNF-, IL-I and IL-6 in the absence of gonadal hormones. Estrogen deficiency
increases inflammatory mediators and leads to the accelerated bone turn over, which is
characterized by an increase in bone resorption relative to bone formation, resulting in
low bone mass and compromised bone microarchitecture (Audran et al., 2001). 
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Inflammatory Mediators and Gonadal Hormone Deficiency-induced Bone Loss
Up-regulation of inflammatory mediators such as TNF-, IL-1 and IL-6 is
associated with the pathophysiology of bone loss which occurs in conditions such as
gonadal hormone deficiency, skeletal unloading as well as chronic inflammatory diseases
(Grano et al., 2002; Pacifici, 1996; Rivera et al., 2003; Speyer et al., 2005). Under normal
conditions, growth factors, cytokines, hormones and adhesion molecules act as the local
messengers to control essentially all biological processes that include cell growth,
development, repair, fibrosis and normal bone remodeling (Manolagas, 2000). However,
the persistent elevation of the pro-inflammatory mediators can disrupt normal bone
remodeling and consequently lead to bone loss (Ishimi et al., 1990; Miyaura et al., 2003;
Romas et al., 2002; Sakuma et al., 2000; Tatakis, 1993). These pro-inflammatory
cytokines, products of stromal cells and monocytes, increase osteoclast differentiation
and bone resorption directly or by up-regulating RANKL and OPG production by
osteoblasts (Theoleyre et al., 2004).
TNF- is considered the main pro-inflammatory cytokine that stimulates
osteoclast activation and inflammatory cytokines produced by macrophages during
estrogen hormone deficiency (Roggia et al., 2001). Decreases in circulating estrogen
stimulate interferon (IFN)- expression by T cells and enhance class II transactivator
(CIITA); a transcriptional co-activator that up-regulates antigen presentation (e.g. class II
MHC) (Cenci et al., 2003) and increases TNF-. Additionally, under gonadal hormone
deficiency TNF- inhibits osteoblast activity, maturation (Abbas et al., 2003; Kikuchi et
al., 2001) and bone mineralization by down-regulating IGF-I (Gilbert et al., 2000) and
ALP (Pischon et al., 2004), and suppressing the expression of transcription factors,
24
Osterix (Lu et al., 2006) and Runx2 (Gilbert et al., 2002). TNF- promotes osteoblast and
marrow stromal cell expression of RANKL, activates RANK signaling in macrophages,
induces osteoclast differentiation and ultimately increases bone resorption activity
(Kanematsu et al., 2000). During the early stages of osteoclastogenesis, TNF- also
increases the osteoclast precursor pool size (Erwig et al., 1998). TNF- inhibitors have
been shown to decrease the CD11b+ osteoclast precursor cells in arthritis patients
(O'Gradaigh et al., 2004; Ritchlin et al., 2003). Furthermore, TNF- under estrogen
deficiency is associated with a defective intracellular antioxidant system (Jagger et al.,
2005) and supplementation with ascorbic acid inhibits TNF--induced osteoclast
precursor cell proliferation and differentiation (Iqbal et al., 2006).
IL-1, which is a pleiotropic cytokine, induces the expression of a large variety of
pro-inflammatory and hematopoietic cytokines such as leukemia inhibitory factor (LIF)
and IL-6 (Dinarello, 1994). Like TNF-, IL-1 initiates a signaling cascade through the
activation of NF-B and c-Jun N terminal kinase (JNK) which promotes osteoclast
survival (Lee et al., 2006). The importance of IL-1 signaling is demonstrated by the fact
that transgenic mice deficient in the IL-1 receptor are resistant to ovariectomy-induced
bone loss (Lorenzo, 1991; Lorenzo et al., 1999) and treatment with IL-1 receptor
antagonist attenuates bone resorption in rheumatoid arthritis patients (Bresnihan et al.,
1998) and inhibits osteoclast activity in the bone marrow of multiple myeloma patients
(Jimi et al., 2004).
Another pro-inflammatory cytokine involved in bone metabolism is IL-6. The
main effect of IL-6 on bone is stimulation of osteoclastogenesis and bone resorption (Dai
et al., 2000; Ota et al., 2001). IL-6 effects are interconnected with those of other pro-
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inflammatory cytokines. For example, IL-6 stimulates osteoclast formation in human
marrow cultures by inducing IL-1 release and the addition of anti-IL-1 inhibits osteoclast
formation induced by IL-6 (Palmqvist et al., 2002). Inversely, IL-6 mediates the
stimulatory effects of TNF-α and enhances PTHrP-mediated hypercalcemia and bone
resorption by increasing the pool of osteoclastic progenitors and their differentiation into
mature osteoclasts (Devlin et al., 1998). IL-6, like other resorptive agents, stimulates
osteoclast activity and bone resorption by an indirect mechanism, increasing interaction
between RANKL and RANK (Nakchbandi et al., 2001).
Other inflammatory mediators that play a role in bone metabolism include the
prostaglandins (PG) (Feyen and Raisz, 1987). Prostaglandin production, especially PGE2,
is regulated primarily by cylcooxygenase (COX)-2 which is highly responsive to
systemic and local cytokines (Miyaura et al., 2003; Raisz, 2001). In bone, prostaglandins
produced by osteoblasts act as potent stimulators of bone resorption by increasing
osteoclast differentiation (Okada et al., 2000) and at the same time are required for
normal bone formation (Li et al., 1995). PGE2 stimulates RANKL production, decreases
OPG secretion by osteoblasts, and up-regulates RANK expression in osteoclasts (Liu et
al., 2005). PGE2 also induces periosteal and endocortical bone formation, principally by
stimulating local osteoprogenitor cells on the adjacent endocortical surface (Ramirez-
Yanez et al., 2004). In PGE2 receptor knock-out mice, osteoclast differentiation and
activity under inflammatory conditions (IL-1 or TNF-) was decreased, providing
support for the role of PGE2 in osteoclast function (Sakuma et al., 2000). Further
evidence of the involvement of PGE2 in osteoclastogenesis was demonstrated by the
observation that osteoclast differentiation and activity were suppressed by treatment with
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COX-2 inhibitors (Suda et al., 2004). Studies have shown that the response of bone cells
to PGE2 is related to the dose and route of COX-2 inhibitor administration (Desimone et
al., 1993; Yao et al., 1999). These agents have been shown to attenuate bone turnover in
postmenopausal women (Raisz, 2001), but long-term effects of potent COX-2 inhibitors
causing too great of a reduction in PGE2 may impair normal osteoblast function (Einhorn,
2003).
Another important inflammatory mediator, nitric oxide (NO) has been recognized
for its role in the pathogenesis of osteoporosis due to its ability to regulate bone turnover
(Pacifici, 1996). Increasing evidence supports a role for NO as an autocrine/paracrine
mediator involved in the regulation of osteoclast (Zheng et al., 2006) and osteoblast
function (Lin et al., 2003). iNOS, the enzyme that catalyzes the conversion of L-arginine
to NO (Cuzzocrea et al., 2003), is involved in mediating the bone loss that occurs in
conditions such as periodontitis (Alayan et al., 2006) and ovarian hormone deficiency
(Cuzzocrea et al., 2003). The inducible forms of NOS are stimulated by inflammatory
mediators such as IFN-, TNF- and IL-1 (Damoulis and Hauschka, 1994; Deng et al.,
1993; Lee et al., 2004a; Palmer et al., 1993). NO is required for bone resorption induced
by IL-1, stimulates osteoclastogenesis through the activation of NF-B, and contributes
to osteoclast survival (Lee et al., 2004; van't Hof et al., 2000). NO also acts in
conjunction with pro-inflammatory cytokines to promote osteoblast cell death (Damoulis
and Hauschka, 1997). Like prostaglandins, NO has dual effects on bone metabolism.
Pharmacological doses of NO donors were reported to increase bone mass in animal
models (Wimalawansa, 2000). These higher concentrations (>100 µM) have been shown
to increase osteoblast activity and nodule formation in vitro (Koyama et al., 2000). In
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contrast, NO plays a role in osteoclastic bone resorption (Jung et al., 2004), and even
though low levels appear essential for osteoclastic activity, higher NO concentrations
inhibit resorption (Chae et al., 1997; Ralston et al., 1995).
Stimulation of osteoclast differentiation and activity by the afformentioned
inflammatory mediators appears to occur, at least in part, through enhanced expression of
RANKL by osteoblasts in the presence of macrophage-colony stimulating factor (M-
CSF). Osteoclasts which differentiate from hematopoietic precursor cells, require factors
that promote their differentiation and survival (Roodman, 1999). Such factors include M-
CSF and RANKL which are produced by osteoblasts as well as activated T lymphocytes.
RANKL acts by binding to its receptor, RANK, on the surface of osteoclast precursor
cells, stimulating their differentiation into mature osteoclasts (Jones et al., 2002; Khosla,
2001). The action of RANKL is prevented by OPG, a soluble decoy receptor expressed
by osteoblasts that competes with RANK for binding to RANKL (Khosla, 2001;
Saidenberg et al., 2002; Schoppet et al., 2002).
RANKL is a protein of 317 amino acids which belongs to the TNF super family
and whose mRNA is largely expressed in bone, bone marrow and lymphoid tissues
(Khosla, 2001). The predominant role of this cytokine in bone is the stimulation of
osteoclast differentiation and activation and the inhibition of osteoclast apoptosis (Fuller
et al., 1998). Together with M-CSF, RANKL is required in vivo for the complete
differentiation of osteoclastic precursors into mature osteoclasts (Jones et al., 2002;
Khosla, 2001). For example, RANKL knock-out mice present with severe osteopetrosis
and loss of osteoclasts (Kong, 1999). RANKL exists both in a soluble and a membranous
forms (Ikeda et al., 2001). The soluble form, which correspond to the c-terminal end of
28
membranous RANKL, may be produced either directly by the cell through an alternative
splicing followed by an excretion in the extra-cellular medium, or by a proteolytic
cleavage of membranous RANKL (Verrier et al., 2004) and then interact with its specific
receptor RANK (Ito , 2005).
RANK is a transmembrane protein of 616 amino acids which belongs to the TNF
receptor (TNFR) super family. This natural receptor of RANKL is expressed primarily on
the cells of the monocyte/macrophage lineage including osteoclastic precursors, B and T
cells, dendritic cells and fibroblasts (Khosla, 2001). RANK is also present at the surface
of mature osteoclasts. RANK, like other TNFR-related proteins, is known to activate a
cascade of intracellular signaling events, including recruitment of TNFR associated factor
proteins (TRAF), activation of transcription factors (i.e. NF-B p50 and p52, activator
protein (AP)-1 and nuclear factor of activated T cells-2), activation of mitogen activated
protein kinase cascades (extracellular regulated kinase, c Jun N terminal kinase) and
induction of Src- and phosphatidylinositol 3 kinase-dependent Akt activation (Lee and
Kim, 2003). The binding of RANKL to RANK stimulates differentiation of osteoclastic
precursors as well as the activation of mature osteoclasts. The RANK activation by
RANKL is followed by its interaction with various components of the signaling pathway
(Hsu et al., 1999a; Lomaga et al., 1999).
OPG which is synthesized as a protein of 401 amino acids is cleaved to give a 380
amino acid mature protein (Khosla, 2001). OPG loses its transmembrane and cytoplasmic
domains and is released as a soluble form by stromal cells and osteoblast cells. Thus OPG
differs from the other members of the TNFR superfamily which remain mainly
membrane associated (Tan et al., 1997). In contrast to RANKL, OPG knockout mice
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become osteoporotic (Mizuno et al., 2002) due to OPG’s ability to bind with RANKL and
down-regulate the RANKL signaling through RANK. OPG represents an antagonist
endogenous receptor that neutralizes the biological effects of all forms of RANKL and
thus acts as an inhibitor of bone resorption (Khosla, 2001; Saidenberg et al., 2002;
Schoppet et al., 2002). The biological effects of OPG on bone cells include inhibition of
terminal stages of osteoclast differentiation, suppression of mature osteoclast activation
and induction of apoptosis (Khosla, 2001; Saidenberg et al., 2002; Schoppet et al., 2002).
It should be noted that OPG can also directly inhibit osteoclastic activity, independently
of RANKL through interaction with a receptor yet to be characterized on osteoclasts
(Hakeda et al., 1998).
A number of factors have been shown to influence RANKL and OPG, and lead to
alterations in the RANKL/OPG ratio. Hormones, vitamins, and other molecules are
known to influence the production of RANKL and/or OPG by stromal osteoblasts and
hence the RANKL/OPG ratio. For example, PTH and glucocorticoid enhance RANKL
and inhibit OPG production (Huang et al., 2004). 1,25-dihydroxyvitamin D3 increases
RANKL production with no effect on OPG (Kondo et al., 2004). Vitamin K has been
shown to stimulate osteoblastogenesis and inhibit osteoclastogenesis in bone marrow
cells through the expression of RANKL (Koshihara et al., 2003). Estrogen and tumor
growth factor  (TGF-) enhance OPG production while IFN- inhibits RANKL induced
osteoclastogenesis (von Stechow et al., 2004). More recently IL-7 has been shown to
induce bone loss via RANKL production by T cells (Lubberts et al., 2003).
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Gonadal Hormone Deficiency and Oxidative Status
Recently, it has been suggested that reactive oxygen species (ROS) play an
important role in postmenopausal bone loss (Basu et al., 2001; Maggio et al., 2003).
Decreasing intracellular antioxidants such as glutathione and thioredoxin has been shown
to increase osteoclast activity via up-regulation of TNF- in ovarian hormone deficient
animal models of osteopenia (Jagger et al., 2005; Muthusami et al., 2005).
Administration of agents that increase the intracellular concentrations of the antioxidant
(e.g. glutathione) in osteoclasts prevents bone loss during estrogen deficiency (Lean et
al., 2003). Inflammatory mediators may deplete physiological antioxidants such as
glutathione or decrease the activity of the enzyme such as glutathione S transferase
(GST) (Miller et al., 2003), superoxide dismutase (SOD) (Mccord and Edeas, 2005) and
heme oxygenase (Chauveau et al., 2005). In response to inflammatory mediators, reactive
oxygen species such as O2-, H2O2, NOO- may be produced that directly or indirectly
enhance inflammation through the activation and phosphorylation of stress kinases (c-Jun
N terminal kinase, extracellular signal regulated kinase, mitogen activated protein kinase
p38) (Haddad, 2002) and redox-sensitive transcription factors such as NF-B and AP-1
(Rahman et al., 2004). Activation of the redox sensitive transcription factor, NF-B, has
been shown to up-regulate inflammatory cytokines (Rahman et al., 2004) and enhance
osteoclastogenesis (Jagger et al., 2005). Thus, compounds that scavenge free radicals
have the potential to down-regulate the inflammatory response (Lean et al., 2003). In
OVX animals, administration of antioxidants (e.g. N-acetyl cysteine or ascorbic acid)
increased bone levels of thiol antioxidants (i.e. glutathione and thioredoxin) and
decreased TNF- production (Lean et al., 2003). Pegylated catalase, a compound that
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breaks down H2O2, decreased bone resorptive activity following ovariectomy (Lean et al.,
2005). In addition to synthetic antioxidants, natural polyphenols which are abundant in
fruits and vegetables, have shown positive effect on bone metabolism under gonadal
hormone deficiency (Fonseca and Ward, 2004; Horcajada-Molteni et al., 2000; Soung et
al., 2006).
Fruit and Vegetable Consumption and Bone Health
Previous epidemiological and experimental studies have shown that consumption
of legumes (Hallund et al., 2006; Engelen et al., 2007), fruits and vegetables (Muhlbauer
et al., 2003; New et al., 2000) rich in phenolic compounds and their derivatives (Hegarty
et al., 2000; Johnell O, 2005), reduce the incidence of chronic inflammatory disease such
as cardiovascular disease, various types of cancers and osteoporosis. Bazzano and
colleagues (Bazzano et al., 2002) reported that adults (25-74 years) consuming fruits and
vegetables 3 times per day experienced a 27% lower cardiovascular disease mortality
(p=0.008) compared to those who consumed fruits and vegetables <1 time per day.
Jansen et al (2004) showed that daily consumption of 200 g of fruit by elderly men (65-
84 years) lowered the risk of lung, colon and prostate cancer. Diets high in fruits and
vegetables have been linked to an increase in bone accrual in boys aged 8-20 y
(Vatanparast et al., 2005) as well as a reduction in the rate of bone loss in pre-menopausal
women (Macdonald et al., 2005) and aging men (Tucker et al., 2002). A retrospective
study with healthy adult women showed that femoral neck BMD was higher in women
who consumed greater amounts of fruits in their childhood (New et al., 2000). These
studies provide strong evidence supporting the importance of fruit and vegetable
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consumption on bone health.
Dried Plums and Bone Health
In terms of fruits with particular bone-modulating properties, dried plum, Prunus
domestica L., has been shown to have potent effects on bone health. A short-term study
of postmenopausal women consuming approximately 100 g of dried plum per day (i.e.
10-12 dried plums) demonstrated that dried plum may enhance bone formation as
indicated by increased serum bone-specific ALP and IGF-I (Arjmandi et al., 2002). 
Muhlbauer and colleagues (Muhlbauer et al., 2003) investigated the influence of various
plant-based foods on bone resorption in male rats. Of the fruit and vegetables considered
in this study, dried plum (1 g/d) proved to be one of the most potent inhibitors of bone
resorption. Studies utilizing female animal models of osteopenia, indicated that diets
supplemented with dried plum not only prevent (Arjmandi et al., 2001), but also reverse
(Deyhim et al., 2005) bone loss due to ovarian hormone deficiency. Other recent studies
evaluating bone recovery following skeletal unloading demonstrated that dried plum had
comparable effects to intermittent PTH therapy on vertebral bone mineral content (BMC)
and trabecular bone volume (BV/TV) of the distal femur (unpublished data). Our recent
report (Franklin et al., 2006) showed that the bone-protective effects of dried plum on
BMD and trabecular bone microarchitecture in gonadal hormone deficient male animals
were even greater than those observed in females. Dietary supplementation with dried
plum prevented the orchidectomy-induced decrease in bone mass and mechanical
strength which was accompanied by improved bone microarchitecture. Serum
biochemical markers of bone metabolism and local gene and protein expression data
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suggested the improved bone quality resulted from increased bone formation and
decreased bone resorption, which was mediated by the IGF-I and RANK pathways,
respectively. These studies provide strong evidence that dried plum may provide a natural
alternative in terms of osteoporosis treatment.
Bone Protective Component in Dried Plum
Despite the very promising findings related to dried plum and bone health in both
male and female animal models, the component of dried plum responsible for the bone-
protective effects remains unclear. Dried plums contain relatively high amounts of boron,
copper, potassium, vitamin K, and phenolic compounds (Stacewicz-Sapuntzakis et al.,
2001). Any one of these components alone or in combination may provide the bioactive
component in dried plum responsible for the bone protective effects.
Dried plum is high in the trace element boron (2-3 mg/100g)(Stacewicz-
Sapuntzakis et al., 2001). The amount of boron in a 100 g serving of dried plums is equal
to the average daily intake for adult males (2.23 ± 1.3 mg/ day). In human and animal
studies, boron deficiency has been shown to increase urinary calcium excretion while
supplementation decreased the excretion of calcium (Nielsen, 2004; Sheng et al., 2001a).
Several animal studies (Armstrong and Spears, 2001; Hunt et al., 1994; Sheng et al.,
2001b) have demonstrated that boron also plays a role in the metabolism of magnesium
and phosphorus ,which are two of the micronutrients required for mineralization of bone
matrix. Additionally, boron supplementation has been shown to increase steroid hormone
concentrations in animals and humans (Hunt et al., 1997). Naghii and colleagues (Naghii
and Samman, 1997) showed that rats consuming 2 mg boric acid/day for 4 weeks
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experienced a significant increase in plasma testosterone. However, other studies have
not observed an effect of boron supplementation on steroid hormone metabolism (Beattie
and Peace, 1993; Gallardo-Williams et al., 2003), so the role of the boron provided by
dried plum on bone in gonadal hormone deficiency remains in question.
In addition to boron, a 100 gram serving of dried plum also contains 20% of the
daily requirement for copper (Stacewicz-Sapuntzakis et al., 2001). Copper plays a key
role in skeletal health as a component of lysyl oxidase, an enzyme involved in collagen-
crosslink formation (Rucker et al., 1998). Collagen crosslinks provide tensile strength to
bone (Riggins et al., 1979) and several animal studies report compromised skeletal
integrity as a result of copper deficiency (Rucker et al., 1975; Smith et al., 2002; Strause
et al., 1987; Teague and Carpenter, 1951). Copper supplementation (15mg/kg diet) has
been shown to prevent the OVX-induced decrease of BMD (Rico et al., 2000). In
humans, a relationship between copper deficiency and osteoporosis has been
demonstrated. Conlan and colleagues (Conlan et al., 1990) reported reduced serum
copper in elderly patients with fractures of the femoral neck compared with age- and
gender-matched controls. Furthermore, copper status was reported to be a more important
predictor of bone health in individuals who were immobilized than calcium status
(Lappalainen et al., 1982). However, in the absence of copper deficiency, copper
supplementation did not improve bone markers (Cashman et al., 2001) and may have
interfered with the anabolic action of other nutrients (e.g. zinc)(Lai and Yamaguchi,
2005). Although adequate copper status is important to bone health, supplementing
copper at the levels found in dried plum is not likely to have anabolic effects capable of
reversing bone loss in gonadal hormone deficient osteopenic animal models.
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Dried plums also have relatively high potassium content (745mg/100g) which has
anti-resorptive effects on bone (Macdonald et al., 2005) and decreased urinary calcium
excretion (Rafferty et al., 2005). Potassium has been recognized for its buffering ability
in reducing blood acidity (Marangella et al., 2004). Metabolic acidosis induces bone loss
by stimulating bone resorption and inhibiting bone formation (Krieger et al., 1992).
Clinical studies with postmenopausal women showed that both potassium intake and fruit
and vegetable consumption decreased dietary acid overload that may have detrimental
effects on skeletal health (Frassetto et al., 2005; Sellmeyer et al., 2002). Higher potassium
intake especially from fruits and vegetables is associated with higher BMD in the elderly
(69-97 year old) (Tucker et al., 2001). The need to encourage adequate potassium intake
from fruit and vegetables is one of the primary reasons for the “5 to 10 a day”
recommendation (Demigne et al., 2004). Due to its strong anti-resorptive properties,
potassium may contribute to dried plum’s potent effects on bone, but the anabolic action
of dried plum previously demonstrated (Deyhim et al., 2005) make the anti-resorptive
action of potassium alone unlikely responsible for the overall effects.
One other micronutrient in dried plum that may account for some of the effects of
dried plum on bone formation is vitamin K (59.5 µg phylloquinone per 100 g DP).
Vitamin K is a fat-soluble vitamin that functions as a cofactor for enzymes involved in
the synthesis of blood coagulation factors and is required to facilitate carboxylation of
proteins such as osteocalcin in bone and reduces urinary calcium excretion (Booth and
Meyer, 1997; Vermeer et al., 1992). In vitro, vitamin K directly stimulates osteoblast
differentiation and inhibits osteoclastogenesis (Koshihara et al., 2003). Observational
studies indicate that vitamin K intake and serum levels are positively related to BMD and
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elderly osteoporotic patients who sustain fractures are often reported to have lower serum
vitamin K (Hart et al., 1985; Szulc et al., 1993; Tamatani et al., 1998). Epidemiologic
studies have also shown that higher vitamin K intake is related to lower fracture
incidence (Booth et al., 2000; Feskanich et al., 1999; Hodges et al., 1993; Stone et al.,
1999). Furthermore, a high percentage of undecarboxylated serum osteocalcin, as seen
with low serum vitamin K, may be a predictor of fracture risk (Kohlmeier et al., 1997b;
Luukinen et al., 2000; Vergnaud et al., 1997). Several vitamin K supplementation studies
(Kohlmeier et al., 1997a; Luukinen et al., 2000; Vergnaud et al., 1997) have found
reductions in calcium excretion and bone resorption, and increased serum levels of
undecarboxylated osteocalcin. Vitamin K supplementation was reported to decrease
serum osteocalcin and lumbar bone mass in children receiving long-term glucocorticoid
treatment (Inoue et al., 2001), and increase serum osteocalcin and ALP during space
flight (Vermeer et al., 1998). A compound derived from vitamin K (i.e. menatetrenone)
had a positive effect on BMD when given to women in large doses with osteoporosis
(Orimo et al., 1998) and strokes (Sato et al., 1998). Pharmacological doses of vitamin K2
(45mg) have also been related to a lower rate of bone loss and a lower incidence of
fracture (Braam et al., 2003). Recently vitamin K has been reported to have anti-
inflammatory properties (Ohsaki et al., 2006). Therefore, vitamin K may possibly
contribute to the effects of dried plum on bone metabolism and further studies are
warranted to determine its contribution.
Polyphenols and Anti-inflammatory Properties
Polyphenols, recognized for their free radical scavenging properties, are perhaps
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one of the most intriguing groups of potential bone protective components in dried plum.
The high polyphenol content in dried plum (1600-3700mg/kg) (Fang et al., 2002;
Nakatani et al., 2000b) results in this dried fruit having one of the highest ratings of
oxygen radical absorbance capacity (ORAC), among the commonly consumed fruits and
vegetables (Dikeman et al., 2004; Fang et al., 2002; Ronald, 1999). The predominant
polyphenols in dried plum are neochlorogenic acid, chlorogenic acid and
cryptochlorogenic acid (Fang et al., 2002). Four more minor phenolic components in
plums include caffeic acid, rutin, cinnamic acid and coumarins (Fang et al., 2002).
Table 1. Composition of phenolic compounds in dried plum (per 100g fruit)
(Stacewicz-Sapuntzakis et al., 2001)
In addition to antioxidant properties, polyphenols have suppressed the synthesis
of inflammatory mediators and/or redox sensitive transcription factors (Carluccio et al.,
2003; Maggi-Capeyron et al., 2001; Pendurthi et al., 2002). For instance, caffeic acid
inhibits the production of TNF- and NO, and the activation of NF-B in hippocampal
cultures (Montpied et al., 2003). Resveratrol, a polyphenol present in most red wines,
decreased the expression of COX-2 and synthesis of prostaglandins by murine
macrophages (Martinez and Moreno, 2000).
These antioxidative and anti-inflammatory properties of phenolic compound are
Phenolic Compounds Amount
per 100 g of Dried Plum
Neochlorogenic acid 131 mg
Chlorogenic acid 44 mg
Rutin 3.3 mg
p-Coumaric acid 1.0 mg
Caffeic acid 0.9 mg
Total Polyphenols 184 mg
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likely to influence the activity of osteoclasts and osteoblasts. For example, quercetins
have been shown to inhibit osteoclast differentiation and activity (Muhlbauer et al., 2003;
Woo et al., 2004), directly stimulate osteoblasts and favorably alter bone formation
markers (Horcajada-Molteni et al., 2000; Mizutani et al., 1998). Flavonoids such as
kaempferol and quercetin, known to suppress iNOS and COX-2 (Chen et al., 2001),
inhibited RANKL-induced osteoclast differentiation and bone resorption activity (Rassi
et al., 2005; Wattel et al., 2003; Wattel et al., 2004; Woo et al., 2004). EGCG, a major
phenolic compound in green tea, suppressed osteoclast formation by inhibiting the
generation of free radicals (Nakagawa et al., 2002). Two of the phenolic compounds in
dried plum, chlorogenic acid and caffeic acid, have been reported to inhibit RANKL-
induced osteoclast differentiation and activity (Kayano et al., 2004; Tang et al., 2006)
while another polyphenol in dried plum, rutin, has been shown to inhibit ovariectomy-
induced osteopenia in rats by decreasing bone resorption and increasing serum
osteocalcin (Horcajada-Molteni et al., 2000). Resveratrol, the major phenolic compound
in grapes, stimulated the proliferation and differentiation of osteoblast cells and increased
intracellular ALP activity and bone morphogenic protein (BMP-2) production (Chang et
al., 2006; Mizutani et al., 1998). Another polyphenol in dried plum, caffeic acid, reversed
oxidative stress (H2O2)-induced decrease of gene expression involving osteoblast activity
such as ALP, type I collagen and phosphorylation of Runx2 (Bai et al., 2004). The results
of these studies indicate that many of the polyphenolic compounds that block oxygen
derived free radicals, down-regulate inflammatory molecules and consequently inhibit
osteoclastogenesis and osteoclast activity (Lean et al., 2003), and stimulate osteoblast
activity. Therefore dried plum which contains high amounts of polyphenols, could
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effectively down-regulate the production of inflammatory mediators that impact
osteoclast and osteoblast activity, signaling and function. Hence the properties of
polyphenols in dried plum which scavenge free radicals and inhibit inflammatory
mediators involved in bone metabolism may account for the beneficial effects of dried
plum on bone health, especially in terms of mediating the effects under inflammatory and
oxidative stress conditions.
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Abstract
This study was designed to investigate the extent to which dried plum (DP)
reverses bone loss in osteopenic orchidectomized (ORX) rats and to compare its effects
to parathyroid hormone (PTH). Fifty, 6-month-old male Sprague Dawley rats were sham-
operated or ORX and bone loss was confirmed after 90 days. The ORX groups were
assigned to control (AIN-93M) diet, 25% DP diet, or PTH (80µg/kg) for 90 days. DP
induced an 11% increase in vertebral and femoral BMD compared to ORX-controls.
BMD in the PTH-treated group was increased by 20.7% (vertebra) and 17.9% (femur).
Vertebral trabecular bone volume (BV/TV) and number were increased by DP and
trabecular separation was decreased compared to controls, which were similar to PTH.
Alterations in trabecular bone of the femur were similar to those in the vertebra, but DP
did not restore BV/TV to the same extent. Cortical thickness was improved by DP and
further enhanced by PTH. DP tended to decrease urinary deoxypyridinoline and calcium,
but did not alter alkaline phosphatase or osteocalcin. We conclude that though the degree
of improvement was not equivalent to PTH with regard to all parameters, DP reverses
bone loss due to ORX and the mechanisms should be further investigated.
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Introduction
While most treatment options for osteoporosis have targeted postmenopausal
bone loss, over the past decade the clinical efficacy of these therapeutic strategies for
osteopenic or osteoporotic males has been evaluated on a more limited basis [1,2].
Clinical trials have shown that in males with osteoporosis, testosterone replacement
therapy (TRT) produces moderate increases in bone mineral density (BMD) [2], but anti-
resorptive therapy (i.e. alendronate) alone [3] or in combination with TRT [4] has a more
pronounced effect. The anabolic agent, parathyroid hormone (PTH), has also been shown
to enhance bone mass of the spine and hip in men with idiopathic disease, and increase
bone turnover [1]. Evidence from studies in male gonadal hormone deficient animals, has
shown that synthetic androgen treatment (i.e. 7-alpha-methyl-19-nortestosterone)
suppresses the accelerated rate of bone turnover and bone loss [5]. Additionally,
bisphosphonates, such as etidronate and alendronate, prohibited bone loss in this model
[6,7] and intermittent PTH markedly increased cortical and trabecular thickness [8]. The
results of these clinical and animal studies indicate the response of gonadal hormone
deficient males to pharmacological therapies is similar to that observed in females.
In addition to pharmacological agents, nutrient supplements and functional foods
[9-11] have also been considered as therapeutic options for men with osteopenia and
osteoporosis, providing a cost effective and convenient alternative with minimal side-
effects [12]. For instance, calcium and vitamin D supplementation (500 mg Ca with 700
IU cholecalciferol) significantly increased femoral neck, lumbar spine, and total body
BMD in healthy men aged 65 and older [11]. However, neither calcium nor vitamin D
supplements alone or in combination have been able to reverse the bone loss [10,13,14].
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Functional foods and their components such as soy proteins [9], isoflavones [15], and
dried plum [16-18] have been evaluated for their ability to attenuate bone loss. Soy
protein, perhaps the most extensively studied natural product in the prevention and/or
treatment of osteoporosis, has been shown to increase serum insulin-like growth factor
(IGF)-I which is associated with bone formation in healthy men [9]. Isoflavones in the
context of both casein and soy protein sources also provided modest protection against
bone loss in orchidectomized male rats [15] by enhancing bone alkaline phosphatase
(ALP), osteocalcin and type I collagen [19]. More recently dried plum (Prunus domestica
L.) has provided some of the most promising evidence of a natural product’s effects on
bone mass and microarchitecture in terms of both prevention and reversal of bone loss
[16-18,20].
Studies utilizing female animal models of osteopenia indicated that diets
supplemented with dried plum could prevent [21] and reverse [16] bone loss due to
ovarian hormone deficiency. Additionally, we have observed that dried plum enhanced
bone recovery in female rats following hindlimb unloading and restored trabecular bone
in a comparable manner to PTH (unpublished data). Muhlbauer and colleagues [17] were
the first to demonstrate that in male rats dried plum strongly inhibited bone resorption
compared to other fruits and vegetables. Our recent report [18] showed that the bone
protective effects of dried plum on BMD and trabecular bone structure in gonadal
hormone deficient male animals was even greater than those previously reported in
females [21]. Dietary supplementation with dried plum prevented the orchidectomy-
induced decrease in bone mass and mechanical strength which was accompanied by
improved bone microarchitecture [18]. The improved bone quality was associated with
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alterations in both bone formation and resorption, which were mediated by the IGF-1 and
receptor activator of nuclear factor-kappa B (RANK) pathways.
Based on our previous findings in orchidectomized males, we hypothesized that
dried plum may have anabolic properties enabling it to reverse bone loss in osteopenic
male animals. Thus, the purpose of this study was to evaluate whether dried plum, a rich
source of polyphenols and micronutrients (e.g. vitamin K, potassium and boron) involved
in bone metabolism [22], could restore the bone mass and structure in gonadal hormone
deficiency-induced osteopenic male rats. Furthermore, the efficacy of dried plum in
reversing bone loss was compared to that of the anabolic agent, PTH.
Materials and Methods
Animals Care, Diet and Necropsy
Fifty, 6-month-old male Sprague Dawley (SD) rats (Harlan, Indianapolis, IN)
were housed in an environmentally controlled animal care laboratory upon arrival.
Animals were acclimated to standard temperature, light:dark (12:12) conditions and AIN-
93 control diet [23] for 5 days. The animals were then anesthetized with ketamine
(70mg/kg body weight) and xylazine (3mg/kg body weight) and either sham-operated
(Sham: one group) or orchidectomized (ORX: four groups) to induce bone loss over a 90
day period. Thereafter, one Sham and one ORX group animals was DXA scanned,
sacrificed, and excised bones analyzed using microcomputed tomography to verify that
bone loss had occurred. The remaining three ORX groups were randomly assigned to
either standard AIN-93M diet (control), control diet with 25% (w/w) dried plum, or
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control diet plus PTH injections (80µg PTH/kg body weight 3 times per week) for an
additional 90-day treatment period. The amount of dried plum incorporated into the diet
was based on the most effective dose from our previous study [18]. The diets were
designed to be isocaloric, isonitrogenous and had similar calcium and phosphorous
content [18]. The dose of PTH utilized in this study was selected based on previous
reports demonstrating significant anabolic effects on bone mass and strength [24] and no
differences in a 3-day compared to a 5-day dosing regimen [25]. The animals were match
fed to the group that consumed the least amount each week, had free access to deionized
water, and were weighed on a weekly basis. At the end of the 90-day treatment period,
rats were placed in metabolic cages and fasted 24 hours prior to necropsy. Urine was
collected in acid-washed tubes over a 12 hour period. Total urine volume was measured,
centrifuged for 20 minutes at 4,000 rpm and aliquotted for calcium, deoxypyridinoline
(Dpd) and creatinine analyses. For necropsy, animals were anesthetized with a mixture of
ketamine/xylazine (70 and 3 mg/kg body weight, respectively) and scanned with dual
energy x-ray absorptiometry (DXA) to measure whole body BMD. Animals were then
bled from the abdominal aorta and serum was separated from whole blood by
centrifugation (4,000 rpm) for 20 minutes and stored at -20˚C. Bones (i.e. left femur and
4th lumbar vertebrae) were collected, cleaned and stored at 4˚C for later analyses. The
coagulating gland, which atrophies in the absence of testosterone [26], was collected and
weighed to confirm orchidectomy. All procedures were performed in strict accordance
with the protocol approved by the Animal Care and Use Committee at Oklahoma State
University.
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Bone Mineral Area, Content and Density
Whole body DXA scans (DXA, Model QDR-4500A Elite, Hologic Waltham,
MA) were performed at the beginning of the study (i.e. baseline), 90 days after surgery
and 90 days post treatment (i.e. final) to assess whole body bone mineral area (BMA),
bone mineral content (BMC), BMD and body composition (i.e. fat and lean mass).
Excised femurs and vertebrae were also scanned to measure the local BMA, BMC and
BMD. All analyses were performed using the Regional High Resolution software
package designed for studying small animals (Hologic Waltham, MA).
Bone Microarchitecture
For determining the effect of dried plum diet on trabecular and cortical bone
architecture, the femur and vertebra were evaluated using µCT (MicroCT40, SCANCO
Medical, Switzerland). The distal end of the femur was scanned and 150 (~2.4 mm) of
the 350 acquired images were analyzed within the volume of interest (VOI). The VOI
was identified by semi-automatically placed contours that included only secondary
spongiosa within the metaphyseal region beginning 25 slices (400µm) from the growth
plate. Cortical bone of the femur mid-diaphysis was evaluated by acquiring 34 slices at
the midpoint, and evaluating 30 (480 µm) of these slices. Trabecular bone of the vertebral
body was scanned in a cranial-caudal direction so that 530 images were acquired. The
VOI was comprised of the secondary spongiosa in 300 cross-sectional slices of the
vertebral body, excluding the growth plate regions. All scans were performed utilizing a
1024 x 1024 matrix resulting in an isotropic voxel resolution of 22 µm3. An integration
time of 70 milliseconds per projection was used with a rotational step of 0.36 degrees. All
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specimens were analyzed at a threshold of 240. The VOI was assessed for structural
parameters including trabecular bone volume per unit of total volume (BV/TV),
trabecular number (TbN), trabecular thickness (TbTh), trabecular separation (TbSp),
structure model index (SMI), linear x-ray attenuation coefficient (Linear Attenuation) and
connectivity density (Connectivity). Cortical parameters included cortical thickness, area,
and porosity and medullary area.
Biomechanical Testing of Vertebra with Finite Element Analysis
The image acquired with µCT allowed further evaluation of the biomechanical
parameters on trabecular bone structures using finite element analysis (FE) software
(Scanco Medical). Previous biomechanical studies have shown that computed
tomography(CT)-based finite element (FE) models are highly correlated with actual
compressive strength of bone specimens [27]. In this study, a micromechanical finite
element (FE) model was constructed by converting bone voxels from the VOI into 8-
node brick elements [28]. The elements in this FE model have linear, elastic and isotropic
material properties described by a Poisson’s ratio of 0.3 and a Young’s modulus of
10GPa [28]. Compression testing was simulated on the reconstructed 3-D images of each
vertebral body based on an average of 970,103 total elements and 1,294,292 nodes. Total
force, which is consistent with ultimate force, physiological force, stiffness, size-
independent stiffness, and average von Misses stresses were determined [29].
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Biochemical Markers of Bone Metabolism
Serum ALP activity, an indicator of bone formation, was measured using an
alkaline phosphatase substrate kit (Bio-Rad Laboratories, Hercules, CA). Total serum
protein was measured by the BCA method [30] and the values of ALP activity were
expressed in nanomol of p-nitrophenol per µg of protein following a 30 minute
incubation period. The intra- and inter- assay coefficients of this process were 4.4 % and
5.7 %, respectively. For the determination of treatment effects on bone resorption, urinary
excretion of Dpd was assessed using the Pyrilinks-D ELISA kit (Metra Biosystems,
Mountain View, CA) and microplate reader (ELx808 Ultra Microplate Reader). The
sensitivity of Dpd measurement is 1.1 mmol/L, and the intra- and inter- assay variability
were 4.8% and 8.4%, respectively. Dpd concentrations were also standardized to
creatinine determined by an ACE clinical analyzer (Alfa Wassermann, West Caldwell,
NJ) based on colorimetric change. The intra- and inter- assay coefficients of variation in
creatinine measurement were 1.0% and 2.6%, respectively.
Statistical Analysis
Statistical analysis was performed using SAS Version 9.0 (SAS Institute, NC).
The significance of treatment effects was analyzed by the one-way ANOVA model
followed by post hoc analysis using the Fisher's least squares means separation test when
F values were significant. Data are presented as means + standard error (SE). In all
statistical comparisons, differences with p<0.05 were considered significant.
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Results
Body Weight, Tissue Weights and DXA
Throughout the treatment period, all animals continued to gain weight and no
differences in body weight were observed among groups (Table 1). Results of body
composition analyses by DXA demonstrated that the consistent body fat percentage and
lean body mass were maintained by all groups (data are not shown). At 90 days post
orchidectomy, coagulating gland weight in ORX-animals were significantly decreased
compared to Sham-control and confirmed the success of orchidectomy (Table1). As may
have been anticipated, whole body BMD was reduced (p<0.005) at 90 days post
orchidectomy, but no significant changes in BMC and BMA were observed (Table 2).
By the end of the treatment period, the dried plum diet restored whole body BMD
to that of the 9-month old sham controls (Table 2). Femoral BMD and BMC (Table 2)
were increased in the ORX-DP group by 6% and 11%, respectively, compared to ORX-
controls. Dried plum diet significantly increased vertebral BMD and tended (p=0.0566)
to increase BMC (Table 2). No change was observed in either femoral or vertebral BMA
with the dried plum diet. A more pronounced increase in BMD of the femur and vertebra
occurred with PTH in conjunction with enhanced BMC. These treatment effects on BMD
by dried plum and PTH were primarily associated with an increase in the amount of bone
mineral rather than a change of bone size.
Microarchitectural Properties of the Femur and Vertebra
Representative reconstructed 3-D images generated from µCT scans of the femur
metaphysis (Figure 1 a-c) and vertebral body (Figure 1 d-f) showed that dried plum
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improved trabecular bone microstructure. Compared to the ORX animals consuming the
control diet, the trabecular network was more evenly distributed, and the struts more
numerous and connected in the ORX-DP group. Additionally, the degree of structural
restoration conferred by dried plum appeared to be similar to PTH-treated group with the
exception of the thickness of the trabecular struts (Figure 1).
These observations from the 3-D images were confirmed by quantifiable changes
in the morphometric parameters. In the distal femur metaphysis the dried plum diet
significantly increased BV/TV (35.7 %) and TbN (23.9 %), and decreased TbSp (33 %)
compared to ORX controls (Figure 2 a,b & d). Dried plum also improved the ORX-
induced alterations in the vertebra by enhancing BV/TV (34.5 %) and TbN (24.4 %), and
depressing TbSp (42.8 %) (Figure 2 a,b & d). The only trabecular parameter that was not
impacted by dried plum in the femur metaphysis and vertebra was TbTh (Figure 2c).
Compared to ORX-controls, the dried plum diet decreased SMI, indicative of a more
plate-like arrangement of the trabeculae in the distal femur (p=0.0358) and tended to
decrease vertebral SMI (p=0.0804) (Table 3). Trabecular bone connectivity in the distal
femur was increased by dried plum diet (p<0.05) and comparable to that of PTH.
However, increases in connectivity density in the vertebra did not reach the level of
statistical significance (p=0.0664) with either treatment. Linear attenuation, a parameter
associated with trabecular density, was increased in the dried plum group at the distal
femur (p<0.0001) and vertebra (p<0.005) compared to ORX-controls. This increase in
linear attenuation was comparable to the effects observed with PTH in the vertebra, but
not in the femur. PTH enhanced BV/TV to a greater extent in the femur metaphysis
(140.5%) than the vertebra (47.4%) and increased TbTh at both sites (i.e. femur=34.3%
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and vertebra=23.3%). Although dried plum did not have as great of an impact on BV/TV
of the femur, its effects on vertebral BV/TV and parameters related to distribution of the
trabeculae (i.e. TbSp and TbN) at both sites, as well as connectivity density in the femur
and linear attenuation of the vertebra were similar to that of PTH.
Analysis of cortical bone at the femoral mid-diaphysis demonstrated that dried
plum significantly increased cortical thickness (20%) and area (15.1%) compared to
controls. PTH decreased the medullary area (p<0.001) in conjunction with increasing
cortical thickness (p<0.0001) and area (p<0.0001). Neither the dried plum diet nor PTH
altered cortical porosity over the 90-day treatment period. Dried plum enhanced cortical
thickness and area, but the extent to which cortical bone was improved was not as great
as that of PTH.
Biomechanical Assessment by FE Analysis
The influence of the dried plum on bone biomechanical properties of the vertebrae
was evaluated by the simulated compression testing with µCT generated data (Table 4).
Compared to the ORX controls, the ORX-DP group experienced an approximately 6-fold
increase in the total and physiological force (p<0.05). There were no statistical
differences between the total and physiological force of the dried plum- or the PTH-
treated groups. However, it should be noted that the PTH induced an 11-fold increase in
the total force and physiological force, respectively, and the variability in the response to
PTH may account for the lack of a statistical difference between the ORX-DP and ORX-
PTH groups. Trabecular bone stiffness was increased (p<0.005) 6-fold with dried plum
which was statistically similar to the PTH response, but size independent stiffness was
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not altered by either treatment. Compared to the ORX-control, dried plum decreased the
average von mises stresses by 66.9% (p<0.005) and the degree of decrease was similar to
that of PTH (71.9%). These results indicate that dried plum significantly improved the
trabecular microarchitecture of the vertebra to the extent that biomechanical parameters
were enhanced.
Bone Biomarkers
As indicators of the treatment effects on bone metabolism, serum ALP and
osteocalcin, and urinary Dpd excretion were assessed. No alterations were observed in
the bone formation markers (i.e. serum ALP & osteocalcin) in response to ORX (data not
shown) or treatments at the end of 90 days (Table 5). Total urinary excretion of Dpd, a
marker of bone resorption, was increased by ORX (data are not shown) at 90 days post
orchidectomy compared to Sham controls. Dried plum suppressed urinary Dpd expressed
as 12 hr total Dpd (Table 5) and Dpd per unit of creatinine by approximately 60%, but
only the 12 hr total Dpd tended to approach statistical significance (p=0.0925).
Additionally, dried plum diet tended to decrease (p=0.0546) urinary calcium excretion by
42.6%, which may be related to net renal acid excretion as well as bone resorption [31].
In contrast, PTH did not alter urinary Dpd or calcium excretion at the end of the 90 day
treatment period in spite of the restoration of bone mass and structure.
55
Discussion
In this study, dried plum was evaluated as an alternative treatment option for
established osteopenia in response to androgen hormone deficiency. The findings of this
study suggest that dried plum markedly improved bone mass, trabecular and cortical bone
microarchitecture, and strength which were negatively impacted by ORX. Vertebral and
femoral BMD were increased by approximately 11% with dried plum compared to
animals on the control diet. The effects of dried plum on vertebral bone density were
approximately 50% of those of the PTH, but dried plum had proportionately a greater
effect (i.e. 60%) on bone biomechanical properties. These finding suggest that dried plum
may positively effect protein matrix synthesis, regulation of osteoblast and osteoclast
activity, and bone turn over rate which are factors that determine overall bone strength
[32]. In contrast to other natural compounds and nutrient supplements such as soy
isoflavones, calcium and vitamin D which demonstrate a limited ability to restore bone
mass and structure [9,15], dried plum effectively increased the bone density and
enhanced both trabecular and cortical microarchitecture.
Previously, Wang et al. [33] reported that after 9 months of age most indices of
bone mass and structure decline in SD males rats. Based on these observations, age-
related bone loss would be expected in the rats used in the current study (i.e. 9 months of
age at initiation of treatment). Even though a Sham control group was not included
during the treatment phase of this study, the increase in whole body BMD in dried plum-
and PTH-treated animals were similar to 9-month-old Sham animals that were used to
confirm bone loss. This suggests that BMD in dried plum- and PTH-treated animals was
recovered during 90 day-treatment period. Dietary supplementation with dried plum
56
restored whole body, femoral and vertebral BMD, which was decreased in response to
gonadal hormone deficiency. This improvement in BMD coincided with increased BMC
and no alteration in BMA suggesting that the restoration of BMD was associated with the
greater bone mineral accrual. There are concerns regarding the abrupt withdrawal of
gonadal hormones in the ORX animal model which does not typically occur in men with
the exception of severe hypogonadism due to castration [34]. A gradual reduction in
serum testosterone and estrogen has been strongly associated with age-related bone loss
in males [35] and therefore, the treatment effects observed with dried plum and PTH in
the ORX animal model in this study likely represent overcoming an exaggerated skeletal
response.
Even though DXA provides a valuable tool for evaluating bone density, areal
BMD measurements are somewhat limited [32]. 3-D assessment of trabecular and
cortical bone microarchitecture provides additional insight into the skeletal response to
treatments. Deterioration of trabecular bone microarchitecture is a common feature of
bone loss due to orchidectomy [35]. Reconstructed 3-D images from µCT showed
marked enhancement of trabecular bone structure in animals consuming the dried plum
supplemented diet which was supported by quantitative data showing in increase in
BV/TV and TbN, and decreased TbSp parameters. Because there were no changes in
trabecular thickness, we hypothesize that the decrease of TbSp may be due to the
formation of new trabaculae rather than thickening of existing trabeculae, but this would
need to be tested in future studies. Previous reports have shown that supplementation
with dried plum restored trabecular BV/TV and TbN in osteopenic ovariectomized and
skeletal unloaded female rat models [16]. The restoration of bone density as well as
57
trabecular bone structure in osteopenic male animals reported here appear to be unique to
dried plum and have not been observed with other natural alternative treatments [36,37].
For example, soy isoflavone prevented the decrease in bone density and trabecular
structures in gonadal hormone deficiency induced osteopenia [15], but could not reverse
the decrease of vertebral BMD and structure after bone loss had occurred [37].
Nonetheless, dried plum was able to restore ORX-induced decrease in bone mass and
structural properties indicating that dried plum may be a potent and effective treatment
option for male osteopenia.
In addition to the deterioration in trabecular bone, cortical bone was also
compromised in response to orchidectomy. Previous animal studies demonstrated that
significant cortical thinning occurs after orchidectomy due to the decrease of cortical
thickness and cortical area [18,8]. Treatment with dried plum increased cortical thickness
and area at the femur mid-diaphysis without affecting medullary area. By comparison,
PTH increased the cortical thickness and area, and at the same time decreased medullary
area. Increased cortical thickness is associated with an increase in periosteal bone
formation on the external surface of the cortical bone, enhanced endocortical bone
formation and/or a decrease in resorption on the endocortical surface [32]. Our results
indicate that the increase of cortical thickness by dried plum may be due to periosteal
expansion rather than an increase in endocortical bone formation as observed with PTH
[8].
Ultimately, prevention of fracture is the goal of any osteoporosis treatment,
therefore the impact of dietary supplementation with dried plum on bone strength should
be considered [35]. Simulated compression testing was utilized with FE analysis
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employing an isotropic model that has been shown to predict the mechanical behavior of
trabecular bone even though it has anisotropic material properties [27]. The dried plum
diet restored trabecular bone strength in this study as demonstrated by the 6-fold increase
in total force, physiological force and stiffness compared to controls. Although the degree
of enhancement of these biomechanical properties was not as great as PTH (i.e. ~11-fold
increase), no statistically significant differences were detected between the two treatment
groups. Simulated compression tests showed that total force was increased with dried
plum to the level of PTH. Dried plum decreased the von mises stress indicating enhanced
resistance to relative deformation. Although the dried plum diet increased stiffness, the
lack of a change when size (cross sectional area of trabaculae within vertebra) is
considered (i.e. size independent stiffness) indicates the increase of stiffness was
attributable to an increase in trabeculae accumulation and distribution rather than an
increase of actual rigidity of bone. Because the mechanical properties of bone are
associated with the quality of bone tissue and its spatial distribution [38], the increased
BMD and the improved trabecular bone microarchitecture in conjunction with the
enhanced bone strength confirm improved bone quality with the dried plum
supplementation.
Similar to our findings with dried plum, drugs and other alternative treatment
which have anti-resorptive or anabolic properties have been shown to attenuate the
process of the bone loss in male hormone deficiency induced osteopenia [8,39]. The
bisphosphonate, etidronate (10mg/kg injection) increased trabecular bone volume and
mineral apposition rate in male rats after orchidectomy [39]. However, in this study [39],
treatments were initiated two weeks post orchidectomy and the short time period to
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induce osteopenia makes it difficult to assess the efficacy of this drug in reversing bone
loss in this animal model. Intermittent PTH has also been used to manage
osteopenic/osteoporotic conditions due to its anabolic properties [25,8]. In this study we
used PTH as a positive control, which enabled us to interpret the degree of anabolic
properties of dried plum. The dose of PTH utilized in this study has been previously
reported to enhance bone density and biomechanical properties [24]. Consistent with
previous findings [40,41], PTH restored the ORX-induced decrease of bone mass,
enhanced cortical and trabecular bone structure as well as bone compressive strength.
Although the effects of dried plum in this study cannot be considered equivalent to PTH,
the marked improvement in bone structural and biomechanical properties suggests that
dried plum has similar anabolic effects.
In lieu of these findings, the question remains as to how dried plum influences
bone metabolism. In this study, there was some indication that dried plum depressed bone
resorption in male osteopenic orchidectomized rats. Total urinary Dpd excretion in
animals fed the dried plum diet was 60.8% lower than ORX control animals and urinary
calcium excretion tended to be reduced compared to controls. Although these results only
represent a single snapshot of the alterations in bone metabolism occurring after 90 days
of treatment, they suggest that changes in bone density and structure induced by dried
plum may be mediated to some extent through suppression of bone resorption. These
changes are similar to other anti-resorptive therapies [7,39] and consistent with previous
observations that dried plum suppressed bone resorption [17,18]. However, anti-
resorptive action alone is not enough for the restoration of bone because suppressing
bone resorption limits the potential increase of bone mass due to the reduction of
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remodeling space [42]. Based on the limitations of anti-resorptive therapies to restore
bone mass and structure, our findings suggest that dried plum may have anabolic
properties. The previous clinical trial and animal studies provide strong evidence of the
bone forming activity of dried plum. For instance, postmenopausal women consuming
approximately 100 g of dried plum per day (i.e. 10-12 dried plums) experienced an
increase in serum bone-specific ALP and IGF-I [20]. Data from animal studies indicate
that dried plum also enhanced circulating IGF-I in orchidectomized male [18] and
ovariectomized female [21] rats. However, as previously mentioned, caution should be
used in the interpretation of biochemical marker data at a single time point to determine
the influence of dried plum on bone metabolism. For example, the effects of treatments
such as PTH on bone formation markers have been reported to occur at early time points
[43] which may explain the lack a detectable change in bone formation markers in the
current study. Further studies examining the influence of dried plum on bone metabolism
over time and at the cellular level are likely to provide more insight in the influence of
dried plum on bone metabolism.
In spite of the very promising findings related to dried plum and bone health in
both male and female animal models and postmenopausal women, the component(s) of
dried plum responsible for such marked effects on bone are still under investigation.
Compared to other fruit and vegetables, dried plums contain relatively high amounts of
polyphenols (184 mg/100g), potassium (732mg/100g) and vitamin K (59.5ug/100g) [22].
Polyphenolic compounds and their derivatives, which constitute many of the pigments in
fruits and vegetables, have been shown to inhibit bone resorption due to their antioxidant
and inflammatory properties [17,44]. In addition to their effects on bone resorption,
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polyphenols also directly stimulate osteoblasts and favorably alter bone formation
markers which would suggest potential anabolic properties [45,46]. Resveratrol, the
major phenolic compound in grapes that has been extensively investigated for its health
benefits, stimulated the proliferation and differentiation of osteoblast cells and increased
intracellular ALP activity and bone morphogenic protein (BMP-2) production [46].
Rutin, which is one of the polyphenols found in dried plums [22] increased serum
osteocalcin and BMD in estrogen deficient osteopenic rats [45], but the effects on bone
mass were not as remarkable as those of dried plum. Apart from the polyphenols, another
potential component of dried plum that may be involved in the bone modulating effects
of dried plum is potassium. Studies have shown that potassium is associated with
enhancing bone health by decreasing bone resorption via its pH buffering capacity
[47,48]. Potassium supplementation also increased bone formation markers such as serum
IGF-I in postmenopausal women [48]. A third component of dried plum known to play a
role in bone metabolism is vitamin K. Vitamin K facilitates the carboxylation of proteins
such as osteocalcin and consequently is involved in bone matrix synthesis [49]. Vitamin
K supplementation was reported to increase serum osteocalcin and lumbar bone mass in
children receiving long-term glucocorticoid treatment [50] and increase osteocalcin and
alkaline phosphatase during space flight [51]. In the current study, no alterations in
osteocalcin or alkaline phosphatase were noted after 90 days of treatment. In vitro,
vitamin K directly stimulates osteoblast differentiation and inhibits osteoclastogenesis
[49]. Although supplemental potassium, vitamin K and individual polyphenols such as
rutin positively influence bone metabolism, no studies to date have reported effects on
bone as pronounced as those observed with the whole dried fruit.
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Although non-pharmacological therapies for osteoporosis may be appealing
treatment options for many individuals, most of these natural alternatives have limited
ability to restore bone density and structure, once bone loss has occurred. In this study we
have shown that as a natural alternative, dried plum has potent effects on bone in terms of
bone mass, microarchitecture and strength in osteopenic male rats. These changes may be
mediated in part through the suppression of bone resorption, but the fact that the
restoration in some of the bone structural and biomechanical parameter shares some
similarities with PTH should not be overlooked. Further investigation is needed on a
mechanistic level to clarify the influence of dried plum on bone metabolism as well as
clinical studies to determine the therapeutic efficacy for men with osteopenia and/or
osteoporosis.
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Figure legends
Figure 1. Reconstructed 3-D images of trabecular bone in the distal femur metaphysis (a-
c) and vertebra (d-f) of osteopenic rats receiving control (AIN-93M) diet (a & d), dried
plum diet (b & e), or PTH injection (c & f) beginning 90 days after orchidectomy.
Figure 2. Alterations in a) trabecular bone volume (BV/TV), b) trabecular number (TbN),
c) trabecular thickness (TbTh) and d) trabecular separation (TbSp) at the distal femur
metaphysis and vertebral body following 90 days of consumption of control diet (ORX-
Control), dried plum (ORX-DP) or parathyroid hormone (ORX-PTH). Bars represent the
mean ± SE for each treatment group (n=7-9 /group). Bars that share the same uppercase
or lowercase are not significantly (p<0.05) different from each other.
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Table 1. Body and Tissue Weights in Sham and Orchidectomized (ORX) Male Rats
Parameters Sham-Control ORX-Control ORX-DP ORX-PTH p-Value
90 Days Post Surgery
Body Weight (g) 469.68 + 5.69 464.5 ± 8.0 0.9967
Coagulating Gland Weight (g) 1.90 ± 0.20a 0.30 ± 0.03b <0.0001
Final (90 Days Post Treatment)
Body Weight (g) 492.33 ± 12.26 472.50 ± 8.92 472.25 ± 16.61 0.4664
Coagulating Gland Weight (g) 0.19 ± 0.01 0.20 ± 0.01 0.22 ± 0.02 0.4436
Values are means ± SE, n=8-9 rats in each group.
For each parameter, values within a given row that do not share the same superscript letter are significantly different (p< 0.05) from each other.
ORX-Control: Orchidectomized rats on control diet based on AIN-93M rodent diet.
ORX-DP: Orchidectomized rats on control diet supplemented with dried plum (25% w/w).
ORX-PTH: Orchidectomized rats on control diet receiving subcutaneous parathyroid hormone injections (80 µg/kg body weight; 3x/wk).
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Table 2. Bone Mineral Area (BMA), Bone Mineral Content (BMC) and Bone
Mineral Density (BMD) in Sham-operated (Sham) and Orchidectomized (ORX)
Rats
Parameters Sham-Control ORX-Control ORX-DP ORX-PTH p-Value
Whole Body
Baseline
BMA (cm2) 67.1871 ± 1.2046 68.3459 ± 0.9280 69.6552 ± 1.1809 70.6611 ± 1.2491 0.1732
BMC (g) 12.0483 ± 0.2168 11.8783 ± 0.3302 12.7612 ± 0.2164 12.4365 ± 0.2917 0.1395
BMD (g/cm2) 0.1795 ± 0.0023 0.1736 ± 0.0029 0.1785 ± 0.0032 0.1806 ± 0.0006 0.2144
90 Days Post
ORX: 
 
BMA (cm2) 76.9824 ± 0.6125 76.7148 ± 1.0905 79.4563 ± 1.0221 77.7913 ± 1.7061 0.3189
BMC (g) 14.1579 ± 0.1701 13.2592 ± 0.2833 13.8877 ± 0.2226 13.8079 ± 0.5013 0.1741
BMD (g/cm2) 0.1839 ± 0.0018a 0.1727 ± 0.0014b 0.1748 ± 0.0015b 0.1772 ± 0.0032b 0.0013
Final:
BMA (cm2) 80.2153 ± 1.5811 77.8680 ± 1.0029 79.1975 ± 1.6247 0.5179
BMC (g) 14.0036 ± 0.3507b 14.4503 ± 0.2612b 15.6332 ± 0.5243a 0.0209
BMD (g/cm2) 0.1745 ± 0.0021c 0.1856 ± 0.0025b 0.1972 ± 0.0040a <0.0001
Femur
BMA (cm2) 2.4001 ± 0.0418 2.4273 ± 0.0460 2.4631 ± 0.0429 0.5854
BMC (g) 0.5762 ± 0.0171c 0.6475 ± 0.0211b 0.7207 ± 0.0220a 0.0001
BMD (g/cm2) 0.2398 ± 0.0039c 0.2663 ± 0.0004b 0.2922 ± 0.0050a <0.0001
Vertebra
BMA (cm2) 0.6461 ± 0.0203b 0.6912 ± 0.0187a,b 0.7490 ± 0.0368a 0.0392
BMC (g) 0.1389 ± 0.0056b 0.1658 ± 0.0056b 0.1956 ± 0.0137a 0.0010
BMD (g/cm2) 0.2147 ± 0.0034c 0.2398 ± 0.0040b 0.2592 ± 0.0062a <0.0001
Values are means ± SE, n=7-9 rats in each group.
For each parameter, values within a given row that do not share the same superscript letter are
significantly different (p< 0.05) from each other.
ORX-Control: Orchidectomized rats on control diet based on AIN-93M rodent diet.
ORX-DP: Orchidectomized rats on control diet supplemented with dried plum (25% w/w).
ORX-PTH: Orchidectomized rats on control diet receiving subcutaneous parathyroid hormone
injections (80 µg/kg body weight; 3x/wk).
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Table 3. Trabecular and Cortical Bone Microarchitecture in Osteopenic
Orchidectomized (ORX) Rats
Parameters ORX-Control ORX-DP ORX-PTH p-Value
Distal Femur Metaphysis
Connectivity (1/mm3) 9.44 ± 1.06b 16.71 ± 1.89a 16.77 ± 2.24a 0.0103
SMI 2.43 ± 0.13a 2.02 ± 0.10b 1.33 ± 0.14c <0.0001
Linear Attenuation 0.86 ± 0.02c 0.99 ± 0.03b 1.17 ± 0.04a <0.0001
Femur Mid-diaphysis
Cortical thickness (mm) 0.59 ± 0.02c 0.71 ± 0.02b 0.80 ± 0.02a <0.0001
Cortical porosity (%) 2.72 ± 0.83 1.88 ± 0.23 1.59 ± 0.25 0.3438
Cortical area (mm2) 5.51 ± 0.18c 6.34 ± 0.21b 6.96 ± 0.20a <0.0001
Medullary area (mm2) 3.92 ± 0.21a 3.61 ± 0.23a 2.75 ± 0.22b 0.0027
Vertebra
Connectivity (1/mm3) 20.41 ± 2.22 27.63 ± 0.98 23.19 ± 2.60 0.0664
SMI 1.06 ± 0.23a 0.52 ± 0.07ab 0.15 ± 0.27b 0.0170
Linear attenuation 1.11 ± 0.07b 1.33 ± 0.02a 1.47 ± 0.08a 0.0030
Values are means ± SE, n=7-9 rats in each group.
For each parameter, values within a given row that do not share the same superscript letter are
significantly different (p< 0.05) from each other.
ORX-Control: Orchidectomized rats on control diet based on AIN-93M rodent diet.
ORX-DP: Orchidectomized rats on control diet supplemented with dried plum (25% w/w).
ORX-PTH: Orchidectomized rats on control diet receiving subcutaneous parathyroid hormone
injections (80 µg/kg body weight; 3x/wk).
Connectivity: Connectivity density.
SMI: Structure model index.
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Table 4. Biomechanical Properties of the Vertebral Body Using Finite Element
Analyses in Osteopenic Orchidectomized (ORX) Rats
Parameters ORX-Control ORX-DP ORX-PTH p-Value
Total Force (N) 225.30 ± 101.93a 1738.65 ±126.21b 2774.03 ± 861.97b 0.0036
Stiffness (N/m x 103) 47.97 ± 20.98a 359.91 ± 27.57b 569.82 ± 176.45b 0.036
Physiological Force (N) 0.68 ± 0.31a 5.21 ± 0.38b 8.32 ± 2.58b 0.0036
Size Independent Stiffness
(N/m)
184.79 ± 178.22 48.76 ± 3.00 72.38 ± 18.05 0.7151
Average Von Mises Stresses
(MPa)
0.317 ± 0.04a 0.105 ± 0.01b 0. 089 ± 0.01b 0.0001
Values are means ± SE, n=12 in each group.
For each parameter, values within a given row that do not share the same superscript letter are
significantly different (p< 0.05) from each other.
ORX-Control: Orchidectomized rats on control diet based on AIN-93M rodent diet.
ORX-DP: Orchidectomized rats on control diet supplemented with dried plum (25% w/w).
ORX-PTH: Orchidectomized rats on control diet receiving subcutaneous parathyroid
hormone injections (80 µg/kg body weight; 3x/wk).
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Table 5. Biochemical Markers of Bone Metabolism
Parameters ORX-Control ORX-DP ORX-PTH P-Value
Serum:
ALP (nmol/g protein) 160.12 ± 19.17 146.3 ± 16.6 164.99 ± 16.6 0.7190
Osteocalcin (ng/ml) 16.3 + 1.2 16.3 + 1.4 12.9 + 1.6 0.2011
Urinary:
12h Total Dpd (nM/L) 4.77 ± 1.50 1.87 ± 0.35 5.64 ± 1.44 0.0925
Calcium (mg/dL) 67.59 ± 10.56 38.83 ± 3.88 65.46 ± 10.38 0.0546
Alkaline phosphatase (ALP); Deoxypyridinoline crosslinks (Dpd)
Values are means ± SE, n=6-9 rats in each group.
ORX-Control: Orchidectomized rats on control diet based on AIN-93M rodent diet.
ORX-DP: Orchidectomized rats on control diet supplemented with dried plum (25% w/w).
ORX-PTH: Orchidectomized rats on control diet receiving subcutaneous parathyroid hormone
injections (80 µg/kg body weight; 3x/wk).
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Abstract
Previous studies demonstrated that dietary supplementation with dried plum
which contains high amounts of polyphenols, counter the detrimental influence of
gonadal hormone deficiency on biochemical markers of bone resorption. This study was
designed to investigate the ability of dried plum polyphenols to down-regulate
inflammatory molecules known to influence osteoclast differentiation and to determine
whether these alterations result in changes in osteoclastogenesis and osteoclast activity
under pro-inflammatory and oxidative stress conditions. To assess the ability of
polyphenols extracted from dried plum to down-regulate nitric oxide and tumor necrosis
factor (TNF)-, murine macrophages (RAW 264.7) were pretreated with the dried plum
extract (0, 10, 20, or 30 µg/ml) and then stimulated with either LPS or hydrogen peroxide
(H2O2). By 8 hr and 16 hr after treatment, dried plum polyphenols dose-dependently
decreased the LPS-induced nitric oxide production by macrophages by as much as 78%.
The polyphenol extract also suppressed H2O2-induced TNF- secretion in macrophages
over time, but exacerbated LPS-induced TNF- secretion. LPS up-regulated
cyclooxygenase (COX-2) and nitric oxide synthase (iNOS), which was attenuated by the
two lower doses of dried plum polyphenols and blocked by the high dose at 16 hrs. Under
normal conditions (i.e. no LPS or H2O2), the polyphenols down-regulated osteoclast
differentiation and activity indicated by TRAP positive cell number and resorption pit
assays. Dried plum polyphenol extract also suppressed (p<0.001) the LPS- or H2O2-
induced osteoclast differentiation and osteoclast activity. During osteoclastogenesis, dried
plum polyphenol extract decreased the LPS-induced NO and TNF- production. In
conclusion, dried plum polyphenols inhibit osteoclastogenesis and osteoclast activity, an
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effect that may be mediated in part by the down-regulation of cytokines such as TNF-,
PGE2 and NO.
Key words: bone, osteoclast, antioxidant, osteoporosis, macrophage
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Introduction
Previous epidemiological and animal studies have shown that the consumption of
fruits and vegetables has beneficial effects on bone health [1,2]. Natural polyphenolic
compounds abundant in plant-based food products are one of the potential groups of
bioactive components responsible for the enhanced bone health [3-5]. Dried plums
(Prunus domestica L.) are a rich source of polyphenols (1.1-2.6 g/kg), neochlorogenic
acid and chlorogenic acid, resulting in this fruit having one of the highest oxygen radical
absorbance capacity among the commonly consumed fruits and vegetables [6,7]. Dried
plum has been shown to prevent [8] and reverse [9] the decrease of bone mineral density
and the deterioration of trabecular bone structure and mechanical strength due to gonadal
hormone deficiency. Our recent report [8] suggested that improved bone quality by dried
plum was in part due to the inhibition of bone resorption, as indicated by decreased
excretion of deoxypyridinoline cross-links and the down-regulation of receptor activator
of NF-B ligand (RANKL) expression.
Normal bone remodeling requires an intricate balance between osteoblast and
osteoclast activity. The pathogenesis of osteopenia or osteoporosis is characterized by
accelerated osteoclast activity relative to the activity of osteoblasts that results in a net
effect of bone loss. Osteoclasts, derived from hematopoietic precursor cells [10], require
RANKL and macrophage-colony stimulating factors (M-CSF) to differentiate into mature
osteoclasts [11]. Under conditions of gonadal hormone deficiency and chronic
inflammation, RANKL-mediated osteoclastogenesis is enhanced by oxidative stress
and/or pro-inflammatory molecules such as tumor necrosis factor (TNF)- [12],
interleukin(IL)-1, IL-6 [13], nitric oxide (NO) [14], and prostaglandin E2 (PGE2) [15]. In
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the case of gonadal hormone deficiency, a reduction of thiol antioxidants (i.e. glutathione
and thioredoxin) has been observed, which is indicative of increased vulnerability to
oxidative stress [16]. The oxidative stress was accompanied with an increase of TNF-
production [12] resulting in increased osteoclast activity and bone loss. In PGE2 receptor
knock-out mice, osteoclast differentiation and activity under inflammatory conditions
(IL-1, TNF-, or LPS) was decreased, providing support for a role for PGE2 and perhaps
cyclooxygenase (COX-2) in osteoclast function [13]. Further evidence of the
involvement of these inflammatory mediators in osteoclastogenesis was demonstrated by
the observation that osteoclast differentiation and activity were attenuated with
supplementation of antioxidants [16] or anti-inflammatory agents (e.g. COX-2 inhibitors)
[15].
Many classes of polyphenolic compounds such as flavonoids [17,18], cathechins
[19,3], and caffeic acids [20] found in fruits and vegetables are capable of scavenging
reactive oxygen species [7,21] and down-regulating inflammatory mediators [22]
associated with osteoclast differentiation and activity. For example, flavonoids such as
kaempferol and quercetin, known to suppress iNOS and COX-2 [22], inhibited RANKL-
induced osteoclast differentiation and bone resorption activity [17,18,23,4].
Epigallocatechin-3-gallate (EGCG), a major phenolic compound in green tea, suppressed
osteoclast formation by inhibiting the generation of free radicals [19]. Two of the
phenolic compounds in dried plum, chlorogenic acid and caffeic acid, have been reported
to inhibit RANKL-induced osteoclast differentiation and activity [7,20]. Rutin, another
polyphenols found in dried plum, has been shown to inhibit ovariectomy-induced
osteopenia in rats, in part by decreasing bone resorption [5]. The results of these studies
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indicate that compounds that block the oxygen derived free radicals down-regulate
inflammatory molecules and lead to the inhibition of osteoclastogenesis and/or osteoclast
activity [16].
Based on our previous in vivo findings related to dried plum’s bone protective
effects in gonadal hormone deficiency models [8,9], we hypothesized that the
polyphenols extracted from dried plum would down-regulate the production of
inflammatory mediators involved in osteoclastogenesis, and inhibit osteoclast
differentiation and activity. The purpose of this study was to investigate the effect of
polyphenols extracted from dried plum on the production of inflammatory mediators in
murine bone marrow macrophages, during their differentiation into osteoclasts and on
osteoclast activity under inflammatory conditions and oxidative stress.
Materials and Methods
Reagents
Murine bone marrow macrophage cells (RAW 264.7) were obtained from
American Type Culture Collection (ATCC No.TIB-71, Rockville, MD). Dulbecco’s
modified eagle medium (DMEM), fetal bovine serum (FBS), and trypsin-EDTA were
purchased from GIBCO-BRL (Grand Island, NY). Penicillin G-streptomycin was
purchased from Sigma-Aldrich (St. Louis, MO). Dried plum powder was provided by the
California Dried Plum Board. For the detection of nitric oxide, sulfanilamide and N-
ethylene diamine dihydrochloride was purchased from Sigma-Aldrich (St. Louis, MO).
Mouse TNF- ELISA kit was purchased from BD Bioscience (San Diego, CA). Anti-
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mouse COX-2, anti-mouse iNOS and -actin were purchased from Santa Cruz (San
Francisco, CA). For TRAP staining, an acid phosphatase kit was purchased from Sigma-
Aldrich (St. Louis, MO). Dentin disc for bone resorption assay were purchased from IDS
(Fountain Hills, AZ). Unless otherwise noted, all other chemicals were reagent grade and
obtained from Fisher Scientific or Sigma-Aldrich.
Extraction of Dried Plum Polyphenols
Polyphenols were extracted from whole dried plum powder using a modification
of the method described by Kim and colleagues [24]. Dried plum powder (10 g) was
diluted with 100 mL of 80% ethanol and sonicated for 20 minutes under pulsated
nitrogen gas to reduce oxidation. Ice was added to the sonicator to ensure that the
temperature did not rise above 20˚C. Following sonication, the solution was filtered
through a Buchner funnel lined with filter paper (Whatman No 4) using a vacuum
system. The remaining residue was then washed with 50 mL of 80% ethanol and the
extraction procedure repeated. The volume of the extract was reduced to 30 ml with roto-
evaporation and then freeze-dried. Total extracted polyphenols were quantified based on
the Folin-Calteau assay [25].
Macrophage Culture
RAW 264.7 murine macrophage cells were maintained in DMEM containing 10%
FBS, 100 U/L penicillin G and 100 mg/L streptomycin at 37˚C in a humidified
atmosphere of 95% air and 5% CO2. The media was changed every 2 days. For the
experiments focused on the macrophage response, cells were plated at a density of 1 ×106
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cells/ml and allowed to adhere for 6 hrs. Cells were then treated with 0, 10, 20 or 30
µg/ml of dried plum polyphenols for 2 hrs and subsequently stimulated with LPS or
H2O2. For the analysis of NO and TNF- production, cell media was collected at 4 hr, 8
hr and 16 hr after LPS (10ng/ml) or H2O2 (100uM) treatment. Protein expression analysis
using western blot techniques was performed on cells harvested at 6 hr and 16 hr post
LPS or H2O2 treatment.
Osteoclast Differentiation and Activity
Experiments were designed to evaluate the effects of the polyphenols on
osteoclastogenesis and osteoclast activity under inflammatory and oxidative stress
conditions. These experiments involved culturing RAW 264.7 macrophages in the
presence of RANKL for 5 days to assess the effects on osteoclast differentiation or 9 days
to determine osteoclast resorption pit formation. Cells were plated in 96-well plates at a
density of 2 ×103 cells/well and allowed to adhere for 16 hrs. Culture medium was
replaced and the cells were treated with 30 ng/ml of RANKL with media changes every 3
days. On day 4, cells were treated with 0, 10, 20 or 30 µg/ml of dried plum polyphenol
extract for 2 hrs and then stimulated with LPS, H2O2 or vehicle. Twenty-four hours post
LPS or H2O2 treatment, the media was collected for the analysis of NO and TNF-, and
osteoclasts were evaluated by TRAP staining as described below.
Osteoclast activity was analyzed by plating macrophages on dentine slice and the
same protocol followed as described above. Cells were incubated for 9 days with 30
ng/ml RANKL and the same doses of polyphenol extract used in the osteoclast
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differentiation experiment. Fifty percent of the media was replaced daily following
stimulation with LPS or H2O2 and on day 9 the resorption pit assay was performed.
Measurement of Nitric Oxide
Nitrite levels were determined using the Griess assay [26]. Briefly, 50 µl of
sample was incubated with the Griess reagent for 10 minutes and the absorbance was
read at 550 nm. The nitrite level in each sample was calculated from a standard curve
generated with sodium nitrite (0-100 µM).
Measurement of TNF-
TNF- production was quantified in cell culture media from macrophages and
during osteoclast differentiation with a commercially available kit. Cell culture
supernatants were collected and centrifuged at 3,000 g for 2 min to remove cellular
debris. Samples (50 µl) were incubated with polyclonal antibodies specific for mouse
TNF- for 2 hrs and then enzyme linked substrate for 30 minute. The intensity of the
color detected at 450 nm (background wavelength 570 nm) was measured after the
addition of a substrate solution and TNF- concentrations were calculated from the
standard curve. The intra- and inter- assay coefficients of variation for this assay were
3.6% and 3.8%, respectively.
Western Blotting
Following the removal of culture medium, macrophages were lysed and aliquots
of total protein (40 µg) were denaturated with SDS buffer (50 mM Tris, pH 6.8, 2% SDS,
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10 % glycerol, 1% bromophenol blue, and 470 mM -mercaptoethanol). SDS-treated
samples were then separated by SDS-PAGE using an 8% resolving gel and electroblotted
to a nitrocellulose membrane. Equal transfer of proteins was confirmed by Ponceau S
staining. After transfer, the membrane was blocked in blocking buffer (5% non fat dry
milk in 20 mM Tris-Cl, pH 7.6) for 2 hrs. The membrane was then incubated with anti-
COX2 (1:200), anti-iNOS (1:200) or anti-actin (1:500) for 2 hrs. The antigens were
detected using chemiluminescent reagent following 1 hr incubation with a horseradish
peroxidase-linked secondary antibody (1:1000) (UVP Bioimaging system, Upland, CA)
TRAP Staining of Multinucleated Osteoclasts
Differentiated osteoclast from RAW 264.7 macrophages were stained for TRAP
expression using an acid phosphatase kit and the number of TRAP-positive
multinucleated (i.e. >3 nuclei) osteoclasts per well were counted. Digital images of the
TRAP staining were taken under bright field microscopy using a Bliss Imaging System
(Bacus Laboratory, Lombard, IL).
Resorption Pit Assay
Following 9 days of culture, cells on dentine disc were removed with exposure to
trypsin-EDTA for 15 minutes and incubated in 0.25 M ammonium hydroxide. Discs were
washed with distilled water, stained with 0.5% (w/v) toluidine blue and images obtained
under light microscopy (Bliss Tracer Version 0.76). Resorption pit area for each well was
determined using a WebSlide Browser 3 and expressed as total resorbed area (µm2) per
each slice.
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Statistical Analysis
Data were analyzed using the one-way ANOVA (SAS Version 9.1, SAS Institute,
NC) with Fisher’s Least Squares test to determine differences among the treatments.
Values were expressed as means ± standard error (SE) and P-values of <0.05 were
considered to be statistically significant. Each experiment was repeated a minimum of 2-
3 times and the representative data are presented.
Results
Macrophage Nitric Oxide and TNF- Production
The effect of dried plum polyphenols on the production of inflammatory
mediators by murine macrophages was investigated by measuring the accumulation of
nitrite, a stable oxidized product of NO at 0, 4, 8 and 16 hr after stimulation with LPS or
H2O2. LPS-induced NO production was detectable at 8 hrs and further increased at 16 hrs
(Figure 1A). Similar to the controls, H2O2-stimulated cells did not produce NO. The
increase in NO associated with LPS was down-regulated (p<0.001) by all three doses of
polyphenols at both the 8 and 16 hr time points compared to controls (Figure 1A) and in a
dose-dependent manner at 16 hrs. 
Compared to the control, TNF- production by H2O2-stimulated macrophages
was increased 2.7-fold at 4 hr and continued to be elevated at 8 and 16 hrs (Figure 1B).
All three doses of dried plum polyphenol extract inhibited H2O2-induced production of
TNF- by 4 hrs (26-28%) and continued to suppress TNF- at 8 and 16 hrs after
treatment (Figure 1B). LPS increased extracellular TNF- up to 1000-fold over time
88
(Figure 1C); all doses of polyphenols unexpectedly exacerbated the LPS-induced
macrophage TNF- production at 8 hr and 16 hr (Figure 1C) and the increase in TNF-
by polyphenols was dose-dependent at 16 hr. Although the polyphenol extract effectively
reduced TNF- production in H2O2-stimulated macrophages, the polyphenols generated
the opposite TNF- response when cells were exposed to LPS.
Expression of Inflammatory-related Proteins
Due to the observation that NO was markedly increased by 8 hrs post LPS, we
measured the expression of iNOS prior to and after this time. LPS up-regulated the
expression of iNOS at 6 hrs after treatment and dried plum polyphenols down-regulated
the LPS-induced expression in a dose-dependent manner (Figure 2A). Sixteen hrs after
LPS, dried plum polyphenol extracts continued to suppress the iNOS expression and the
highest dose of dried plum polyphenols (30 µg/ml) essentially blocked protein expression
(Figure 2A) indicating that dried plum polyphenols down-regulated macrophage NO
production by inhibiting iNOS protein expression.
LPS up-regulated COX-2 expression at both 6 and 16 hrs post treatment (Figure
2B). Except for the lowest dose (10 µg/ml), the polyphenol extract down-regulated the
expression of COX-2 at 6 hrs and continued to suppress at 16 hrs. Consistent with the
iNOS data, the highest dose of dried plum polyphenol extract (30 µg/ml) blocked the
expression of COX-2, but only at 16 hrs (Figure 2B).
No differences in the expression of -actin were observed with any treatments
compared to control at both 6 and 16 hrs post LPS (Figure 2C). Neither control cells nor
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cells exposed to H2O2 expressed iNOS (data are not shown), which is consistent with the
lack of NO production.
Nitric Oxide and TNF- Production During Osteoclastogenesis
Extracellular NO and TNF- production was also assessed during
osteoclastogenesis to investigate whether dried plum polyphenols altered the production
of inflammatory cytokines during osteoclast differentiation. Following 4 days of
exposure to RANKL, LPS increased the NO by more than 8-fold compared to controls at
24 hrs (Figure 3A). Treatment with polyphenols dose-dependently (p<0.001) decreased
LPS-induced NO production. In contrast to the macrophages, dried plum polyphenols
dose-dependently (p<0.001) inhibited LPS-induced TNF- production by 35%, 56% and
78% in the 10, 20 and 30 µg/ml, respectively (Figure 3B); however, the level of
inhibition did not reach the level of the control. In line with the observations in the
macrophage cultures, H2O2 failed to stimulate cells to produce detectable levels of NO
during osteoclast differentiation (data are not shown). None of the doses of polyphenol
extract altered H2O2-induced TNF- (data are not shown).
Osteoclast Differentiation
To determine the effect of dried plum polyphenol extract on osteoclast
differentiation under normal, LPS- or H2O2-stimulated conditions, the number of TRAP-
positive, multi-nucleated cells were counted per well (Figure 4). In the absence of LPS-
or H2O2-stimulated osteoclastogenesis, 20 and 30 µg/ml of dried plum polyphenol extract
inhibited differentiation of osteoclast up to 32.2% (Figure 4A & 5A). Both LPS and
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H2O2 significantly increased RANKL-induced osteoclast differentiation by 127% and
30%, respectively (Figure 4B & C). As illustrated in Figure 5B and 5C, both LPS and
H2O2 treatment increased the size of the osteoclast, the staining density and number of
nuclei in each individual osteoclast cell compared to cells treated with RANKL alone. All
three doses of dried plum polyphenol extracts (10, 20 and 30 µg/ml) inhibited LPS-
induced osteoclast formation (Figure 4B). The inhibition of osteoclast differentiation by
the highest dose (30 µg/ml) of polyphenols was 89% higher (p<0.01) than the lowest
dose (10 µg/ml) and comparable to the level of the control. The polyphenols also dose-
dependently inhibited H2O2-induced osteoclast formation (Figure 4C). The two higher
doses of polyphenols more effectively inhibited (p<0.05) osteoclast differentiation than
the lowest dose. In addition to osteoclast number, a decrease in osteoclast size and TRAP
staining density were observed with all three doses of dried plum polyphenol extract
(Figure 5B & C).
Osteoclast Activity
LPS increased (p<0.05) the resorption pit area by 274% (Figure 6A) compared to
the control. As illustrated in Figure 6A, LPS increased number of resorption pits as well
as the resorption area. Treatment with the three doses of polyphenols significantly
reduced the effects of LPS on osteoclast activity as indicated by a decrease in the
resorption pit area by 63%, 87% and 90%, respectively (Figure 6B). This level of
suppression by all doses was comparable to the control (Figure 6B). The resorption area
was significantly increased by H2O2 treatment and dried plum polyphenol extract
decreased the H2O2-induced increase in resorption pit area by as much as to 94% and all
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doses of polyphenols suppressed osteoclast activity below that of the controls (Figure 6C
& D). These results suggest that the dried plum polyphenol extract significantly inhibited
the activity of osteoclasts in conjunction with the suppression of their differentiation.
Discussion
Natural phenolic compounds have been proposed as one group of potential
bioactive components in fruits such as dried plum responsible for the beneficial effects on
bone metabolism [27,28]. In this study we investigated the influence of polyphenols
extracted from dried plum on osteoclasts and found that the polyphenols suppressed
osteoclast differentiation and activity under normal conditions as well as in conditions of
oxidative stress and inflammation. This inhibition of osteoclastogenesis and resorpting
activity occurred in conjunction with down-regulation of the inflammatory mediators,
NO and TNF-. Due to the increase in inflammatory mediators and ROS associated with
gonadal hormone deficiency-induced bone loss [16], the results of this study provide
further insight into the mechanisms by which dried plum preserves bone mass and
microarchitecture as reported in our previous in vivo studies [8,29]. Although the
polyphenols in dried plum are known for their potent free radical scavenging capacity
[30,31], this study is the first to demonstrate that polyphenols extracted from dried plums
down-regulate inflammatory mediators in osteoclast precursor cells and inhibit their
differentiation into mature, bone resorpting osteoclasts.
In recent years, inflammatory mediators such as NO have been recognized for
their role in the pathogenesis of osteoporosis due to their ability to regulate bone turnover
[32]. iNOS, the enzyme that catalyzes the conversion of L-arginine to NO [33], is
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involved in mediating the bone loss that occurs in conditions such as periodontitis [34]
and ovarian hormone deficiency [35]. NO is required for bone resorption induced by IL-
1, stimulates osteoclastogenesis through the activation of NF-B, and contributes to
osteoclast survival [36,37]. In the current study, dried plum polyphenols decreased the
LPS-induced production of NO in pure macrophage cultures and during the
differentiation of macrophages into osteoclasts. Down-regulation of NO by dried plum
polyphenols was associated with decreased expression of iNOS by macrophages, similar
to that observed with the synthetic antioxidant, pyrrolidine dithiocarbamate (PDTC) and
the iNOS inhibitor, NG-nitro-L-arginine methyl ester (L-NAME) [37]. Lee and
colleagues showed that both PDTC and L-NAME decreased iNOS expression and
osteoclast differentiation in bone marrow cells. Previous studies have demonstrated that
inflammatory stimuli (e.g. interferon- and LPS) up-regulate iNOS and COX-2 protein
over a similar time course and that a physical interaction occurs between these two
proteins [38]. Due to this interaction, iNOS inhibitors are capable of preventing PGE2
synthesis [38,39] and therefore reduce PGE2-mediated osteoclast differentiation [13].
COX-2 inhibitors are likewise known to suppress osteoclast differentiation and osteoclast
enzymatic activity [15]. As anticipated, the down-regulation of iNOS expression with the
dried plum polyphenols observed in this study occurred in conjunction with COX-2
inhibition. Other natural phenolic compounds such as kaempferol and epigallocatechin
have been shown to have similar anti-inflammatory properties and to down-regulate
osteoclastogenesis [19,4]. These phenolic compounds suppress RANKL-induced
osteoclast differentiation and inhibit signaling kinases (e.g. c-Jun-terminal kinase, p38
MAP kinase) and transcription factors (e.g. NF-B and AP-1) which regulate iNOS and
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COX-2 expression. Thus, future studies should investigate whether the inhibition of
iNOS and COX-2 associated with dried plum polyphenol treatment results from
alterations in these same transcription factors and signaling kinases as observed with
these other polyphenolic compounds or whether the polyphenols from dried plum have
unique mechanisms of action.
Additionally, we have reported here that during osteoclastogenesis dried plum
polyphenols decreased TNF- production under both inflammatory and oxidative stress
conditions. TNF- is one of the primary pro-inflammatory cytokines responsible for the
increase in bone resorption occurring with gonadal hormone deficiency [32]. During the
early stages of osteoclastogenesis, TNF- increases the osteoclast precursor pool size
[40] and TNF- inhibitors have been shown to decrease the CD11b+ osteoclast precursor
cells in arthritis patients [41]. Erwig et al [42] demonstrated that the antioxidant, ascorbic
acid, was capable of inhibiting TNF- induced osteoclast precursor cell proliferation and
differentiation [43]. Our data suggest that dried plum polyphenols may have decreased
osteoclastogenesis and osteoclast activity by inhibiting the action of TNF- when
macrophages were exposed to RANKL [40] or directly blocked TNF- receptor mediated
pathways. Activation of the redox sensitive transcription factor, NF-B, up-regulates
inflammatory cytokines [44] and may synergistically enhance osteoclastogenesis [12].
Thus, compounds that scavenge free radicals such as chlorogenic acid derivatives, the
primary class of polyphenols in dried plum, have the potential to down-regulate the
inflammatory responses [16,31,45]. In animal models of osteoporosis, administration of
antioxidants (e.g. N-acetyl cysteine or ascorbic acid) increased bone levels of thiol
antioxidants (i.e. glutathione and thioredoxin) and decreased TNF- production [16].
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Pegylated catalase, a compound that breaks down H2O2, decreased bone resorptive
activity following ovariectomy [46]. Thus decreased TNF- production by dried plum
polyphenols may occur as a direct effect on H2O2 or inhibition of ROS involved in
signaling pathways that produce TNF-.
Although dried plum polyphenol extracts significantly reduced TNF- production
during osteoclastogenesis and in H2O2-stimulated macrophages, the opposite response
was observed when the LPS-stimulated macrophage cultures were treated with
polyphenols. Previous studies [47,48] have demonstrated that antioxidant treatments do
not always have uniform effects on inflammatory mediators. For instance, PDTC
increased TNF- production by LPS-stimulated macrophages, but decreased TNF- in
zymosan-stimulated (i.e. cell wall component of Saccharomyces cerevisiae that utilize
protein kinase C activation) macrophages [47]. Ito and colleagues [49] also reported that
LPS-induced production of TNF- and IL-1 was different in pure macrophages compared
to osteoclast cultures. Hence, variations in the production of inflammatory cytokines and
their action on osteoclast differentiation appears to be dependent on the osteoclast’s stage
of maturation [15].
Aside from the inhibition of pro-inflammatory cytokines, dried plum polyphenols
also suppressed osteoclast differentiation induced by exposure to RANKL (30 ng/ml)
under normal conditions. Osteoclastogenesis is dependent on intracellular signaling
molecules downstream of cFms and RANK including the adaptor protein, TNF receptor-
associated factor (TRAF), the transcription factor, NF-B, and the nuclear factor of
activated T cells (NFAT)c1. Our findings suggest that dried plum is capable of inhibiting
osteoclastogenesis independent of exogenous oxidative stress or inflammatory
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conditions. This observation is comparable to other studies with polyphenolic compounds
such as caffeic acid and chlorogenic acid that decrease osteoclastic function by
suppressing NFATc1, the master transcriptional factor for osteoclast differentiation [50].
Caffeic acid also decreased the gene expression of cathepsin K [20], the primary cystein
protease involved in bone resorption, and led to a marked decrease of osteoclastic bone
resorption in rats with adjuvant-induced arthritis. The potential for dried plum
polyphenols to decrease NFATc1 and proteolytic enzyme activity should be investigated
to further clarify the mechanism which osteoclast activity was decreased.
Although the dried plum polyphenol extract effectively suppressed osteoclast
differentiation, this extract was comprised of several types of phenolic compounds. It is
unclear at this point whether the effects on osteoclasts reported here are the results of an
individual phenolic compounds or the action of the polyphenols as a whole. Based on the
literature [3,23,4], it would seem that a number of phenolic compounds, may have the
ability to suppress osteoclast differentiation and activity, but whether there are
differences in the potency of these compounds remains to be determined. In addition to
the issue of the potency of polyphenolic compounds, many issues remain to be addressed
related the alterations in these compounds’ chemical structure that occur during the
absorption and metabolism of these compounds [51,52].
In summary, we have shown that dried plum polyphenols suppressed osteoclast
differentiation and activity under oxidative stress and inflammatory conditions. These
effects on osteoclasts occurred in conjunction with down-regulation of NO and TNF-
production. The findings of this study suggest that the polyphenols in dried plum are at
least in part responsible for the anti-resorptive effects of dried plum reported in previous
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animal studies [8,9]. Additional investigations is needed to further determine the specific
targets and other potential mechanisms by which dried plum’s polyphenols inhibit
osteoclastogenesis and depress osteoclast activity, including key transcription factors
associated with osteoclast differentiation under both normal and stress conditions. It
should also be noted that even though this study has focused on the anti-resorptive
properties of dried plum’s polyphenols, the magnitude by which dried plum restores bone
mass and microarchitecture in osteopenic animal models [9,53] is not likely to be
explained solely by the action of polyphenols on osteoclast. Investigation of the influence
of these polyphenols on osteoblast proliferation and function should also be considered.
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Legends for Figures
Figure 1. Effect of dried plum polyphenols on (A) nitric oxide (NO) and (B & C) TNF-
production in macrophages. Cells were plated at 1 × 106 cells/ml, treated with 0, 10, 20 or
30 µg/ml of dried plum polyphenol extracts and then stimulated with (A & C) LPS (10
ng/ml) or (B) H2O2 (100 µM) for 4, 8 or 16 hrs. At a given time point, bars that share the
same letters are not significantly different (p<0.05) from each other. PP10: 10 µg/ml of
dried plum polyphenols, PP20: 20 µg/ml of dried plum polyphenols, PP30: 30 µg/ml of
dried plum polyphenols.
Figure 2. Down-regulation of (A) iNOS and (B) COX-2 protein expression by dried plum
polyphenols in LPS-stimulated macrophages. -actin (C) was used as a control. Cells
were plated at 1 × 106 cells/ml and treated with 0, 10, 20 or 30 µg/ml of dried plum
polyphenol extracts and then stimulated with LPS (10 ng/ml) for 6 and 16 hr.
Figure 3. LPS-induced (A) NO and (B) TNF- production was suppressed by dried plum
polyphenols during osteoclastogenesis. Cells were exposed to RANKL for 4-days and
then treated with 0, 10, 20 or 30 µg/ml of dried plum polyphenols for 24 hr. Bars that
share the same letters are not significantly different (p<0.05) from each other.
Figure 4. Dried plum polyphenols inhibit osteoclast differentiation as indicated by the
number of TRAP positive cells per well under inflammatory and oxidative stress
conditions. Cells were cultured with RANKL (30 ng/ml) for 4 days and treated with 0,
104
10, 20 or 30 µg/ml of dried plum polyphenol extracts for 2 hrs prior to stimulation with
(A) Control medium, (B) LPS (10 ng/ml) or (C) H2O2 (100 nM). Cells were harvest 24 hr
later. Bars that share the same letters are not significantly different (p<0.05) from each
other.
Figure 5. Representative slides (5X & 20X) showing TRAP staining of LPS and H2O2
stimulated osteoclasts following treatment with 0, 10, 20 or 30 µg/ml of dried plum
polyphenol extract. As shown, polyphenols decreased TRAP positive (purple color) cell
number and size under (A) normal conditions, as well as with (B) LPS (10 ng/ml) and (C)
H2O2 (100 nM) stimulation.
Figure 6. Effects of dried plum polyphenol extracts on (A& B) LPS (10 ng/ml) or (C&D)
H2O2 (100 nM) induced osteoclasts activated as indicated by resorption pit area. Cells
were cultured with RANKL (30 ng/ml) for 4 days and then treated with 0, 10, 20 or 30
µg/ml of dried plum polyphenol extracts for 2 hr prior to stimulation with LPS (10 ng/ml)
or H2O2 (100 nM). Media with the respective treatments was replaced daily and discs
were stained with toluidine blue on day 9. Bars that share the same letters are not
significantly different from each other.
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Abstract
Previous studies have demonstrated that dietary supplementation with dried plum
can restore bone mass and structure, and significantly increase indices of bone formation
such as alkaline phosphatase (ALP) and insulin-like growth factor (IGF)-I. Potential
bioactive components in dried plum responsible for these anabolic effects include its
polyphenols that maintain potent antioxidant and anti-inflammatory properties. The
purpose of this study was to determine how dried plum polyphenols influence osteoblast
(MC3T3-E1 cells) activity and mineralized nodule formation under normal and
inflammatory conditions. Cells were plated and pretreated with polyphenols (0, 2.5, 5, 10
and 20 µg/ml) extracted from dried plums and 24 hrs later stimulated with TNF- (0 or
1.0 ng/ml). Intra- and extracellular ALP activity was measured at 7 and 14 days and
mineralized nodule formation assessed at 28 days. Dried plum polyphenols at 5, 10 and
20 µg/ml significantly increased intracellular ALP activity under normal conditions at 7
and 14 days. Polyphenols also restored TNF- -induced suppression of ALP activity at 14
days (p<0.001) and the restoration was comparable to the controls. Polyphenols increased
mineralized nodule formation as evidenced by an increase (27.7%) in density of Alizarin
red S staining and number of mineralized nodules. In the absence of TNF-, 5 µg/ml of
polyphenols significantly up-regulated IGF-I mRNA levels compared to controls.
Increases in Runx2 and Osterix expression induced by polyphenols under normal
conditions did not reach statistical significance. TNF- decreased the expression of
Runx2, Osterix, and IGF-I, and polyphenols restored their mRNA levels to that of the
controls. In the absence of TNF-, the lowest dose of polyphenols down-regulated the
expression of RANKL. As expected, TNF- up-regulated RANKL mRNA and the 5, 10
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and 20 µg/ml doses of polyphenols decreased RANKL expression without altering OPG.
We conclude that dried plum polyphenols enhance osteoblast activity and function under
normal and inflammatory conditions by up-regulating growth and transcription factors as
well as attenuating the inflammatory response.
Key words: bone, antioxidants, osteoporosis,
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Introduction
Normal bone remodeling is maintained by a balance between bone formation and
bone resorption (1). Conditions in which bone formation by osteoblasts is decreased
relative to the activity of bone resorpting osteoclasts may result in a net loss of bone mass
(2-4). Osteoblasts, fibroblast-like cells derived from a mesenchymal lineage, synthesize
enzymes and matrix proteins involved in the formation of mineralized bone (5) and serve
as a source for osteoclast differentiation factors including receptor activator of NF-B
ligand (RANKL) (2;4;6). Inflammatory cytokines such as tumor necrosis factor (TNF)-
and interleukin (IL)-6 decrease osteoblast activity and at the same time stimulate
osteoblasts to produce inflammatory cytokines such as RANKL, prostaglandin E2 (PGE2)
and IL-1 that can enhance osteoclast differentiation and activity (7-9).
In gonadal hormone deficiency, TNF- has been identified as one of the
predominant pro-inflammatory mediators of bone loss (10). TNF- inhibits osteoblast
activity and bone mineralization by down-regulating growth factors such as insulin-like
growth factor (IGF)-I (11) and alkaline phosphatase (ALP) (12) involved in the formation
of hydroxy apatite, and decreasing the expression of lysyl oxidase, the enzyme
responsible for collagen crosslinking (13). Suppression of osteoblast activity by TNF- is
associated with down-regulation of transcription factors, Osterix (14) and Runx2 (15),
which regulate the expression of ALP and IGF-I as well as several bone matrix proteins
including osteopontin and bone sialoprotein (16). TNF- also alters osteoblast signaling
by increasing RANKL production which promotes osteoclast differentiation and activity
(17;18). Under conditions of gonadal hormone deficiency, decreased osteoblast activity
and promotion of osteoclast differentiation by inflammatory cytokines such as TNF- are
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associated with a defective antioxidant system (19). Supplementation with antioxidants
attenuates ovariectomy-induced bone loss by suppressing TNF- and enhancing bone
formation (20).
Polyphenolic compounds and their derivatives, which reside in fruits and
vegetables, have antioxidant and anti-inflammatory properties that have been shown to
influence both osteoclasts and osteoblasts. For example, polyphenols inhibit osteoclast
differentiation and activity (21;22), directly stimulate osteoblasts, and favorably alter
bone formation markers (23;24). Caffeic acid, one of the polyphenols in dried plums
(Prunus domestica L.), has been reported to reverse the oxidative stress (H2O2)-induced
decrease in ALP and type I collagen expression by osteoblasts as well as the
phosphorylation of Runx2 (25). Resveratrol, the major phenolic compound in grapes,
stimulates the proliferation and differentiation of osteoblasts and increases intracellular
ALP activity and bone morphogenic protein (BMP-2) expression (24;26). Rutin is
another polyphenol found in plums (27) and is reported to increase serum osteocalcin and
BMD in estrogen deficient osteopenic rats (23). These data suggest that a variety of
individual phenolic compounds modulate osteoblast activity and signaling, and perhaps
certain combinations may have anabolic effects on bone.
Dried plum, a rich source of polyphenols (27), has been shown to positively
influence bone mass, bone microarchitecture, and serum markers of bone metabolism
(21;28-30). A short-term study of postmenopausal women consuming approximately 100
g of dried plum per day (i.e. 10-12 dried plums) demonstrated that dried plum increased
serum bone-specific ALP and IGF-I (29). Data from animal studies indicate that dried
plum enhances circulating IGF-I in gonadal hormone deficiency models of osteoporosis
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(30;31) and was more effective than estrogen replacement in restoring bone in osteopenic
ovariectomized female rats (28). Although other plant-based foods with relatively high
phenolic compound content such as soy favorably modulate bone metabolism, their
ability to restore bone in osteopenic animal models appears to be somewhat limited (32).
Recently, dried plum’s ability to restore bone mass and microarchitecture in osteopenic
gonadal hormone deficient male rats was compared to the anabolic agent, parathyroid
hormone (PTH). Although dried plum was not as potent as intermittent PTH therapy in
restoring all bone parameters, it completely reversed the decrease in bone mass compared
to sham-operated control animals and had similar effects to PTH on vertebral bone and
biomechanical properties (33).
Based on the findings from these animal and clinical studies (34;35), we
anticipate that components of dried plum such as its polyphenolic compounds, mediate
these anabolic effects on bone by altering osteoblast signaling, maturation, and/or activity.
Hence, the purpose of this study was to investigate how polyphenols extracted from dried
plum stimulate osteoblast activity and mineralized nodule formation under normal and
inflammatory conditions.
Materials and Methods
Reagents
MC3T3-E1 (RIKEN No. RCB1126), mouse calvarial pre-osteoblastic cells were
obtained from Riken BioResource Center (Ibaraki, Japan). Minimum essential medium
(-MEM), fetal bovine serum (FBS) and penicillin G-streptomycin were purchased from
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GIBCO-BRL (Grand Island, NY). Ascorbic acid, -glycerophosphate, alizarin red-S and
mouse TNF- were purchased from Sigma-Aldrich (St. Louis, MO). Dried plum powder
was generously provided by the California Dried Plum Board. For ALP activity
measurements, an alkaline phosphatase substrate kit from Bio-rad (Hercules, CA) was
used. Unless otherwise listed, all other chemicals were reagent grade and obtained from
Fisher Scientific.
Experiment 1
The objective of Experiment 1 was to evaluate the effects of polyphenols
extracted from dried plum on osteoblast activity and function under normal and
inflammatory conditions. MC3T3-E1 cells were plated at a density of 1 ×105 cells/ml in
6-well plates (n=3) and cultured in -MEM containing 10% FBS, 2 mM L-glutamine and
100 U/L penicillin G and 100 mg/L streptomycin at 37 ˚C in a humidified atmosphere of
95% air and 5% CO2 for 48 hrs. After cells reached confluence, the medium was replaced
with -MEM containing 10 mM -glycerophosphate and 25 µg/ml ascorbic acid to
facilitate in vitro mineralization. Cells were then treated with 0, 2.5, 5, 10 or 20 µg/ml of
dried plum polyphenols for 24 hrs and then stimulated with 0 or 1 ng/ml of TNF-.
Culture medium, which included TNF- and the dried plum polyphenol doses described
above, was replaced every three days. For ALP activity measurement, culture media and
cell monolayers were harvested at 7 and 14 days after confluence. For analysis of
mineralized nodule formation, cells were fixed at 28 days and stained with Alizarin red S
as described below.
119
Extraction of Polyphenols from Dried Plum
Polyphenols were extracted from whole dried plum powder using a modified
version of the method described by Kim and colleagues as previously reported (36;37).
Ethanol extraction was repeated twice using 80% ethanol while sonicating with pulsated
nitrogen gas. The volume of the extract was reduced using roto-evaporation and then
freeze-dried. The total extracted polyphenols was quantified based on the Folin-Calteau
assay (38).
Intracellular and Extracellular ALP Activity
After 7 days and 14 days of treatment with polyphenols, media was collected and
the cell monolayer was gently washed twice with ice-cold phosphate buffered saline
(PBS). Cells were lysed with 0.2% Triton x-100, the lysate was centrifuged at 14,000 × g
for 5 min, and the clear supernatant was used for the measurement of ALP activity and
protein concentration. ALP was determined based on the conversion of p-nitrophenyl
phosphate to p-nitrophenol by spectroscopy at 405 nm according to the manufacturer’s
instruction (Bio-Rad, Hercules, CA). Total protein was assessed using the BCA method
(39) and ALP activity was expressed in nanomol of p-nitrophenol produced per min per
µg of protein.
Nodule Formation
The extent of mineralized nodule formation based on staining density and number
of nodules was determined by Alizarin Red S (AR-S) staining at 28 days. Briefly, cells
were washed twice with PBS and then fixed in ice-cold 70% ethanol for 1hr at room
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temperature. Following another wash with PBS, cells were stained with 40 mM Alizarin
red-S (pH 4.2) for 10 min at room temperature. Digital images of the stained matrix were
acquired using a digital camera (Canon, Japan) and the number of mineralized nodules
per well was counted. For the quantification of staining density, AR-S staining was
released from the cell matrix by incubation with 10% cetylpyridinium chloride in 10 mM
sodium phosphate (pH 7.0) for 15 min. The Alizarin red-S concentration was determined
by measuring the absorbance at 562 nm.
Experiment 2
Experiment 2 was designed to investigate the dose-dependent effects of TNF-
and polyphenols alone and in combination on osteoblast gene expression. Cells were
plated in 6-well plates at a density of 1 ×105 cells/ml and allowed to adhere for 24 hrs.
Culture medium was replaced with differentiation media containing 10 mM -
glycerophosphate and 25 µg/ml ascorbic acid and the cells were treated with 0, 1 or 10
ng/ml of TNF- to determine the alterations in gene expression associated with escalating
dose. Eighteen hours post TNF- stimulation, cells were harvested and total RNA
isolated for the analysis of mRNA expression.
To evaluate the effects of dried plum polyphenols on gene expression under
normal and inflammatory conditions, cells were plated in 6-well plates at a density of 1
×105 cells/ml and allowed to adhere for 24 hrs. Culture medium was replaced with the
differentiation media as described above. Twenty-four hrs later the cells were pre-treated
with 0, 2.5, 5, 10 or 20 µg/ml of dried plum polyphenols followed by stimulation with 0
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or 1 ng/ml of TNF-. After eighteen hours of exposure to TNF-, the cells were collected
for the analysis of mRNA levels.
Analysis of Gene Expression Using Real Time PCR
Total cellular RNA was isolated using Trizol following the manufacturer’s
guidelines (Invitrogen, Rockville, MD, USA). The concentration and purity of the RNA
were determined by OD’s measured at 260 nm and 280 nm. The expression of mRNA
was quantified by real time RT-PCR using a Mx3005p (Stratagene, La Jolla, CA, USA)
with Light Cycler RNA Amplification Kit SYBR green I (Roche, Penzberg, Germany).
Denatured RNA (50 ng) from cells was reverse transcribed and amplified with gene
specific primers (Table 1) under the following conditions: Reverse transcription at 58° C
for 10 min, inactivation of reverse transcriptase at 95° C for 30 s, and 45 cycles of 94° C
for 15 s, 60° C for 20 s and 72° C for 20 s. Post-PCR melting curves confirmed the
specificity of single-target amplification. The amount of mRNA for each gene was
calculated using a standard curve generated from 10-fold dilutions of control RNA
(Roche, Penzberg, Germany) and expression levels were normalized to GAPDH.
Statistical Analysis
Statistical analysis was performed using SAS Version 9.0 (SAS Institute, NC).
The significance of treatment effects was analyzed by one-way ANOVA followed by
post hoc analysis using the Fisher's least squares means separation test. Values were
expressed as means + standard error (SE) and difference between treatments was
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considered to be significant at p<0.05. Each experiment was performed 2-3 times and the
representative graph or picture is presented.
Results
Cell Viability
No cytotoxic effects of dried plum polyphenol extract were observed on the
MC3T3-E1 cells at the doses used in this study (data not shown). Additionally, increasing
dose of dried plum extract did not significantly alter cell viability as measured by the
resazurin assay.
Intracellular and Extracellular ALP Activity
Dried plum polyphenol extract stimulated ALP activity in MC3T3-E1 cells under
normal conditions at 7 day and 14 days (Figure 1A). The increase in ALP activity was
greater than 50% with the two higher doses at day 14. TNF- treatment significantly
reduced the ALP activity by 29% and 38% at day 7 and 14, respectively (Figure 1B). In
the presence of TNF-, only the 10 µg/ml dose of polyphenols significantly elevated
intracellular ALP at 7 days, but all doses enhanced ALP activity by 14 days compared to
cells receiving TNF- alone (Figure 1B). In addition to intracellular ALP, the ALP
released by the cells into the media was assessed. At day 7, no dose of dried plum
polyphenols altered the extracellular ALP activity under either normal or inflammatory
conditions (Figure 2A & 2B). After 14 days, all doses of polyphenols increased (p<0.05)
extracellular ALP activity under normal conditions with the exception of the 20 µg/ml
dose (Figure 2A). Similar to the intracellular response, TNF- treatment significantly
123
reduced the ALP activity at day 7 and 14 (Figure 2B). ALP activity was increased (p<
0.01) by the 2.5, 5, and 10 µg/ml doses of polyphenols after 14 days compared to the
cells receiving TNF- and 0 polyphenols.
Nodule Formation
To determine the effect of dried plum polyphenols on osteoblast function, cells
were stained with Alizarin red S (AR-S) at 28 days post-confluence for the identification
of mineralized nodules (Figure 3 & 4). In the absence of TNF-, only the 10 µg/ml dose
of dried plum polyphenols significantly increased the staining density (Figure 3 B), but
both the 5 and 10 µg/ml doses increased (p<0.05) the number of nodules (Figure 3 C).
The increase in lowest dose (2.5 µg/ml) and highest (20 µg/ml) doses of polyphenols did
not reach the level of significance suggestive of a biphasic effect. At 28 days, there was
an apparent TNF- induced decrease (p< 0.01) in mineralized nodule formation (Figure
4A) which was supported by the decrease of AR-S staining density (Figure 4B) and
number of mineralized nodule (Figure 4C). The decrease in AR-S staining density
resulting from TNF- was significantly increased by the all doses of polyphenols. The 10
µg/ml of polyphenols had the greatest effect (i.e. 162% increase in staining density)
compared to the cells receiving TNF- only and restored nodule staining density to that
of the controls (Figure 4B). Dried plum polyphenols prevented the TNF--induced
reduction in the number of mineralized nodule, but the increase did not reach the level of
the control cells. These data showing that dried plum polyphenols increased the number
and size of mineralized nodules under normal and inflammatory conditions suggest that
increased ALP by dried plum polyphenols increases mineralized nodule formation.
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Alterations in Gene Expression
The effects of TNF- on the mRNA levels of osteoblast transcription and growth
factors, as well as cytokines involved in osteoclast differentiation were assessed. TNF-
dose-dependently (p<0.01) suppressed the expression of Runx2 and Osterix (Figure 5A).
In addition to the transcription factors, TNF- dose-dependently (p<0.01) decreased the
expression of IGF-I, with a 70% reduction observed with the higher dose of TNF-
(Figure 5B). The 1 and 10 ng/ml of TNF- increased (p<0.05) the expression of RANKL
by 3-fold and 4-fold, respectively, while no alterations in OPG expression were observed
(Figure 5C). These results suggest that TNF- decreased ALP activity and mineralized
nodule formation by down-regulating transcription and growth factor related to osteoblast
maturation.
Ability of dried plum polyphenols to stimulate gene expression involving osteoblast
maturation and activity
Dried plum polyphenol extract did not significantly alter the expression of Runx2
and Osterix in MC3T3-E1 cells under normal conditions (Figure 6A). In the presence of
TNF-, 2.5 and 5 µg/ml doses of polyphenols completely restored (p<0.01) the TNF-
induced down-regulation of Runx2 expression to the level of control (Figure 6B).
Although higher doses of polyphenols did not significantly increase the Runx2
expression, increase of expression was similar to the level of control. The decrease in
Osterix expression resulting from TNF- was restored by 2.5 and 5 µg/ml of polyphenols
to the level of the controls, but the difference did not reach the level of significance
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compared to cells receiving TNF- alone (Figure 6B). In addition to transcription factors,
the 2.5, 5 and 10 µg/ml doses of dried plum polyphenols increased the expression of IGF-
I up to 63% under normal conditions (Figure 7A), but only the 5 µg/ml dose reached the
level of statistical significance. The highest dose (20 µg/ml) of polyphenols increased (p<
0.001) the expression of IGF-I by ~2-fold in the presence of TNF- (Figure 7B). Dried
plum polyphenols did not significantly increase the TNF--induced reduction in IGF-I
expression, but the increase in expression reached the level of the control cells (Figure
7B). These data indicate that the increase in ALP activity and mineralization by dried
plum polyphenols were associated with the increase in growth factor and transcription
factors under inflammatory conditions. However, under normal conditions, the increase
only in growth factor by dried plum polyphenols may influence the increased osteoblast
activity.
Effect of dried plum polyphenols on RANKL and OPG expression
In the absence of TNF-, only the 2.5 µg/ml dose of dried plum polyphenols
significantly down-regulated the expression of RANKL but the medium doses (5 and 10
µg/ml) of polyphenols did not alter the RANKL expression suggestive of a biphasic
effect. Dried plum polyphenol did not significantly alter the OPG expression compared to
the control (Figure 8A). In the presence of TNF-, the 5, 10 and 20 µg/ml doses of
polyphenols suppressed the TNF- induced up-regulation of RANKL expression by 50%
(Figure 8B). However, dried plum polyphenols did not alter the OPG expression. These
results indicate that dried plum polyphenols attenuate TNF- induced inflammatory
response in MC3T3-E1 cells.
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Discussion
This study demonstrates that dried plum polyphenols stimulate osteoblast activity
by increasing ALP activity and mineralized nodule formation under normal and
inflammatory conditions. These changes were mediated in part through the up-regulation
of growth and transcription factors which were down-regulated by TNF-. Increased
ALP and mineralization in conjunction with decreased RANKL expression in the
presence of TNF- also indicate that dried plum polyphenols may inhibit the osteoblast
signaling associated with inflammatory mediators. These findings are similar to those
reported in ORX animals (30), which demonstrated the dried plum’s ability to suppress
the ORX-induced increase in RANKL expression. These results suggests that dried plum
polyphenols have anabolic potential and may provide an explanation as to how dried
plum increases bone mass and improves bone microarchitecture in established osteopenic
animals (28;30;40).
TNF- is considered a central inflammatory cytokine involved in the
pathophysiology of bone loss in a variety of conditions and has been shown to inhibit
osteoblast activity and bone mineralization in both in vitro and in vivo studies (12;41).
These effects on osteoblasts result from the down-regulation of growth factors (e.g. IGF-
I) (42) and depressed enzymatic activity (12) (e.g. ALP) involved in the formation of
mineralized bone matrix. In this study, TNF- suppressed osteoblast activity, the
osteoblasts’ ability to form mineralized nodules and was associated with the down-
regulation of IGF-I and transcription factors, Runx2 and Osterix. The binding of nuclear
Runx2 (15) and Osterix (14) to osteoblast specific elements up-regulates skeletal genes
and consequently stromal cells develop the osteoblast phenotype. Runx 2 has been
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described as a master transcription factor in osteoblast differentiation from stromal
mesenchymal cells to mature osteoblasts (43) and regulates the expression of ALP and
IGF-I as well as several bone matrix proteins (16). In addition to Runx2, the transcription
factor, Osterix, regulates the expression of genes that function in osteoblast activity and
maturation (14). For example, overexpression of Osterix increases the gene expression of
bone sialoprotein, ALP, osteocalcin and osteopontin and mineralized nodule formation
(44). Previous studies have shown that suppression of osteoblast activity by TNF-
occurs in response to decreased transcriptional activity and reduced mRNA stability
(14;15). Also, the promoter region for Runx2 contains a homologous sequence of NF-B
and AP-1 binding sites that are capable of conferring responsiveness to TNF- (15) and
could suppress osteoblast activity. Anti-inflammatory drugs or compounds that suppress
NF-B or AP-1 signaling may therefore counter the negative effects of TNF- on Runx2
expression in osteoblasts (25). Hence, our data suggest that inflammatory conditions
induced by TNF- down-regulate Runx2 and Osterix as well as the growth factor, IGF-I,
and therapies that can counter these effects may be able to restore osteoblast activity and
function.
In addition to the alterations in osteoblast activity, TNF- also up-regulated
osteoblast signaling for osteoclast differentiation and activity by increasing RANKL
expression. This finding is consistent with previous reports in which an increase in
RANKL mRNA levels mediated by TNF- resulted in an increase in osteoclastogenesis
and osteoclast activity both in vivo and in vitro studies (17;18;45;46). The role of the
TNF superfamily of transmembrane proteins (i.e. RANK, RANKL and OPG) in
osteoclastogenesis via the RANK-RANKL complex has been described (47;48). When
128
the ligand, RANKL, binds with its receptor, RANK, osteoclast differentiation and
function is enhanced (48). OPG, which is also produced by bone marrow stromal cells
and osteoblasts, is a soluble decoy and therefore inhibits RANK-RANKL mediated
osteoclastogenesis (48). In this study, OPG was unaltered by TNF-, however, the
changes of OPG expression by TNF- or other inflammatory mediator reported in other
literature are still inconclusive (49;50). The result of these alterations in RANKL with no
change in OPG expression was a significant elevation of the RANKL/OPG ratio under
the inflammatory conditions produced by TNF-. By enhancing the signaling for
osteoclastogenesis and osteoclast activity signaling and at the same time depressing the
osteoblast activity, TNF- creates potentially a worse case scenario for bone metabolism.
The intent of this study was to evaluate how dried plum polyphenols influenced
osteoblasts under both normal and inflammatory conditions. Under normal conditions
dried plum polyphenols increased ALP, an effect that appeared to be mediated by an
increase in IGF-I, and countered the TNF- mediated decrease in ALP activity. ALP is
the enzyme involved in mineralization of the skeleton due to its ability to catalyze the
hydrolysis of organic phosphate esters, thereby providing inorganic phosphates for
mineralization or by removing the inorganic pyrophosphate that inhibits calcification
(51;52). ALP has been widely accepted as a marker of bone formation/osteoblast activity
in clinical and animal studies (53;54). For example, increased BMD in response to PTH
was correlated with increased bone-specific ALP activity in postmenopausal women with
osteoporosis (54). Also natural compounds beneficial to bone health such as soy
isoflavones and polyphenols (e.g. rutin) are associated with an increase in ALP activity
(23;53). Although dried plum polyphenols restored the TNF- induced suppression in
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ALP activity at 14 days, there were no significant changes at 7 days indicating that cells
need to be exposed to polyphenols for a period of time to positively influence bone
mineralization. In this study, the increase in ALP in the presence of TNF- was
associated with up-regulation of transcription factors Runx2 and Osterix. Similar to our
findings with dried plum, drugs and other natural compounds which have anabolic
properties have been shown to increase osteoblast activity by up-regulating transcription
factors and/or growth factors. For example, the soy isoflavone, genestein increased the
ALP activity and Runx2 expression in osteoblasts (55). The anabolic agent, PTH,
increased mineralized nodule formation and that was mediated by increased mRNA
expression of Runx2 and Osterix in osteoblast cultures (56). In addition to transcription
factors, PTH restored bone mass, an effect mediated by increased IGF-I expression (57).
The role of IGF-I in bone metabolism has typically been associated with the stimulation
of osteoblast activity, inhibition of collagen matrix degradation, T-cell proliferation, and
myeloid cell growth and differentiation (57-59). IGF-I has been shown to influence bone
mass and skeletal acquisition (60;61) although the precise mechanism remains unclear
(62). In this study dried plum polyphenols increased osteoblast expression of IGF-I which
is consistent with previous studies with postmenopausal women (63) and osteoporosis
animal models (30). IGF-I seems to play a major role in mediating the effects of dried
plum on bone formation.
In this study, RANKL was down-regulated in cells treated with the dried plum
polyphenols indicating the influence of dried plum polyphenols on the osteoblast in vitro
is consistent with the findings from our animal study (30). We had previously
demonstrated that dietary supplementation with dried plum decreases the expression of
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RANKL in orchidectomized rats (30). Recently we have reported that dried plum
polyphenols depress RANKL-induced osteoclast differentiation and osteoclast activity
(unpublished data) and have anti-inflammatory properties as indicated by the down-
regulation of TNF- and nitric oxide (37). These results related to osteoclasts combined
with the findings of the current study provide strong support for the anti-resorptive action
of the polyphenols in dried plum.
Mineralization of the extracellular matrix of bone is initiated by mineral crystal
formation (64). Matrix vesicles containing ALP are formed by budding from the cell
surface membrane. Mineral aggregation and propagation occurs along the collagen fibrils
and form the mature nodule (65;66). In this study dried plum polyphenols increased
mineralized nodule formation in normal and inflammatory conditions. Although
promising results have been shown with all doses of dried plum polyphenols, the degree
of mineralization by the highest dose (20 µg/ml) was not as effective as the lower doses.
Although there are a number of possible explanations for this effect, one possibility
relates to chelation of minerals. Normally, the extracellular matrix contains sufficiently
high concentrations of Ca2+, Pi and other trace amount of minerals (e.g. magnesium,
fluoride, citrate, iron, zinc) for mineralization (67). In spite of the health benefits of
polyphenols, some concern remains related to the metal/mineral ion chelating properties
of polyphenols (68). As such, it is possible that the high dose of polyphenols chelated
some essential minerals required for nodule formation. Further studies to evaluate the ion
exchange (e.g. Ca) using isotope labeling techniques may provide information as to
whether chelation is a factor.
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At the present, there are a number of issues that remain related to the polyphenols
in dried plum. For instance, it is unclear whether the effects on osteoblasts reported here
are the results of an individual phenolic compound or the action of the polyphenols as a
whole. It is also unclear whether there are differences in the potency of these
polyphenolic compounds. Studies using the available synthetic versions of the phenolic
compound in dried plum or proportionate formulations of those found in the fruit may
provide the opportunity to clarify the polyphenols’ effects on osteoblasts and to address
whether the effects reported here are the results of individual compounds or the action of
the polyphenols as a whole. Although several types of the polyphenolic compounds
found in dried plum have been shown to favorably influence osteoclasts or osteoblasts
(25;69;70), their ability to prevent bone loss or restore bone to the extent of dried plum in
pre-clinical and clinical studies (28;30;40;63) appears to be somewhat limited (32).
Furthermore, the alterations in gene expression presented here were the results of
alterations that occurred after only 48 hours of exposure to the polyphenols and may or
may not represent the long-term effects. Based on dried plum’s impact on ALP activity
and mineralized nodule formation, it seems that evaluation of these polyphenols on gene
expression over time is warranted.
In this study dried plum polyphenols effectively enhanced the osteoblast activity
and function under normal and inflammatory conditions, and these effects were mediated
by an increase of growth and transcription factors, and attenuation of the inflammatory
response to TNF-. The findings of this study suggest that the polyphenols in dried plum
are at least in part responsible for the anabolic effects of dried plum reported in previous
animal studies (28;40). In spite of these promising results, studies conducted separately
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from osteoclasts and may leave some uncertainty as to the clear effects of dried plum or
its polyphenols on interaction of osteoblasts and osteoclasts. Future studies are warranted
that include the simultaneous evaluation of these cellular activities using co-culture
systems.
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Legends for Figures
Figure 1. Effect of dried plum polyphenol extracts on intracellular ALP activity in
MC3T3-E1 cells. Cells were plated at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10 or 20
µg/ml of dried plum polyphenol extracts alone (A) or stimulated with TNF- (1 ng/ml)
(B) for 7 and 14 days.
Figure 2. Dried plum polyphenols increased extracellular ALP activity in MC3T3-E1
cells. Cells were plated at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10 or 20 µg/ml of dried
plum polyphenol extracts alone (A) or stimulated with TNF- (1 ng/ml) (B) for 7 and 14
days. Bars that share the same uppercase or lowercase letter are not significantly different
from each other.
Figure 3. Dried plum polyphenols increase mineralized nodule formation as indicated by
Alizarin red S staining (red color) density (A & B) and number of mineralized nodule (C)
under normal conditions. Cells were plated at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10
or 20 µg/ml of dried plum polyphenol extracts alone for 28 days. Bars that share the same
letter are not significantly different from each other.
Figure 4. Mineralized nodule formation by dried plum polyphenols under inflammatory
conditions. Cells were plated at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10 or 20 µg/ml of
dried plum polyphenol extracts and stimulated with TNF- (1 ng/ml) for 28 days.
Alizarin red S staining (red color) density (A & B) and number of mineralized nodule (C)
were measured. Bars that share the same letter are not significantly different from each
other.
Figure 5. TNF- induced alterations in mRNA expression of (A) Runx2 and Osterix, (B)
IGF-I and (C) RANKL and OPG. Cells were plated at 1 × 105 cells/ml and stimulated
with TNF- (1 and 10 ng/ml) for 18 hrs.
Figure 6. Effects of dried plum polyphenols on TNF- induced alterations in mRNA
expression of Runx2 and Osterix. Cells were plated at 1 × 105 cells/ml, treated with 0,
2.5, 5, 10 or 20 µg/ml of dried plum polyphenol extracts alone (A) or stimulated with
TNF- (1 ng/ml) (B) for 18 hrs. Bars that share the same uppercase or lowercase letter
are not significantly different from each other.
Figure 7. Dried plum polyphenols increase mRNA expression of IGF-I. Cells were plated
at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10 or 20 µg/ml of dried plum polyphenol
extracts alone (A) or stimulated with TNF- (1 ng/ml) (B) for 18 hrs.
Figure 8. Effects of dried plum polyphenols on TNF- induced alterations in mRNA
expression of RANKL and OPG. Cells were plated at 1 × 105 cells/ml, treated with 0, 2.5,
5, 10 or 20 µg/ml of dried plum polyphenol extracts alone (A) or stimulated with TNF-
(1 ng/ml) (B) for 18 hrs. Bars that share the same uppercase or lowercase letter are not
significantly different from each treatment.
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Table 1. Primer sequences for real time PCR
Transcript Sequence (5’-3’)
RANKL F: CTG ATG AAA GGA GGG AGC AC
R: GAA GGG TTG GAC ACC TGA ATG C
OPG F: TCC TGGCAC CTA CCT AAA ACA GCA
R: ACA CTG GGC TGC AAT ACA CA
Runx2 F: TGC TTC ATT CGC CTC ACA AA
R: TTG CAG TCT TCC TGG AGA AAG TT
Osterix F: CCT CTC GAC CCG ACT GCA GAT C
R: AGC TGC AAG CTC TCT GTA ACC ATG AC
IGF-I F: CTT CAC ATC CTC TCT ACC T
R: ATT CTG TAG GTC TTG TTT CC
GAPDH F: CCG GTG CTG AGT ATG TCG
R: CCC TGT TGC TGT AGC CGT A
142
Figure 1. Intracellular ALP activity
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Figure 2. Extracellular ALP activity
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Figure 3. Nodule formation under normal conditions
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Figure 4. Nodule formation under inflammatory conditions
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Figure 5
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Figure 6
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Figure 7
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Figure 8
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CHAPTER VI
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS
Summary
The purpose of this research project was to further our understanding of the
molecular and cellular mechanisms by which dried plum and/or its polyphenols improve
bone mass and microarchitecture. In Study 1, the dried plum diet (25%, w/w) restored
bone mass (i.e. BMC and BMD) and trabecular microarchitecture in 9-month-old male
osteopenic orchidectomized rats over the course of 90 days. These effects on trabecular
bone, especially trabecular bone of the vertebral body, were similar to those produced by
intermittent PTH therapy (80 µg/kg x3 per wk). Study 2 was designed to assess the
effects of polyphenols extracted from dried plum (0, 10, 20, or 30 µg/ml), one of the
groups of potential bioactive components in dried plum, on osteoclastogenesis and
osteoclast activity. The polyphenols (10, 20, and 30 µg/ml) decreased the production of
inflammatory mediators (i.e. NO and TNF-) and reduced the number of TRAP-positive
cells and the size of the resorption pits when the cells were stimulated with either LPS or
hydrogen peroxide (H2O2). In Study 3, murine pre-osteoblasts (MC3T3-E1) were pre-
treated with polyphenols extracted from dried plum (0, 2.5, 5, 10, or 20 µg/ml) to
determine their influence on osteoblast activity, function and signaling under normal and
inflammatory (i.e. stimulation with TNF-) conditions. The polyphenols (2.5, 5, 10, and
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20 µg/ml) enhanced ALP activity and mineralized nodule formation. These findings
suggest that dried plum may have anti-resorptive and anabolic properties that are
mediated in part by its polyphenols.
Conclusions
The purpose of this research project was to investigate the molecular and cellular
mechanisms by which dried plum and its polyphenols improve bone mass and
microarchitecture. To accomplish this purpose, the following 7 hypotheses were
developed and tested.
Hypothesis 1: Dried plum supplementation will restore bone density and
trabecular bone microarchitecture in osteopenic gonadal hormone deficient male rats and
these effects will be similar to the anabolic agent, PTH.
The dried plum group experienced an increase (p<0.05) in vertebral (11.7%) and
femoral (12.4%) BMD compared to ORX controls. Vertebral BV/TV and TbN were
increased by dried plum (p<0.05) and TbSp was decreased. These changes in trabecular
structural properties were comparable to those observed with PTH. Alterations in
trabecular bone of the distal femur metaphysis were similar to those observed in the
vertebra, but BV/TV was not restored to the same extent. Cortical thickness at the femur
mid-diaphysis was also improved by dried plum, but the extent to which cortical bone
was improved was not as great as that of PTH. Enhanced bone biomechanical properties
of the vertebrae (i.e. total force and von mises stress) evaluated by the simulated
compression testing indicated that dried plum significantly improved the trabecular
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microarchitecture of the vertebra to the extent that biomechanical parameters were
enhanced. The findings of this study suggest that dried plum markedly improved bone
mass, trabecular and cortical bone microarchitecture, and strength which were negatively
impacted by ORX. However, the degree of the anabolic effects on BMD and some
parameters of bone microarchitecture were not as great as the effects of PTH. Based on
the inability of dried plum to improve all parameters, we fail to accept Hypothesis 1. It
should be noted when considering the effects of dried plum compared to a potent
anabolic agent such as PTH that the ability of dried plum to restore bone is quite
remarkable and shows much more promise than other natural compounds evaluated.
Hypothesis 2: Osteopenic ORX male rats consuming the dried plum
supplemented diet will experience an increase in serum ALP, but a decrease in urinary
Dpd and calcium excretion. The alterations in ALP will be similar to the effect of PTH,
but the decrease in bone resorption indicators will not mimic PTH.
No statistically significant alterations were observed in serum ALP activity or
urinary excretion of Dpd or calcium in response to 90 days of dried plum or PTH
treatment. Dried plum tended to suppress urinary 12 hr total Dpd excretion (p=0.0925) by
approximately 60% and calcium excretion (p=0.0546) by 42.6%; however, PTH did not
affect either of these indicators of bone metabolism. It is important to note that the age of
the animals and the duration of the experiment likely influenced this lack of statistically
significant effects. Bone formation markers have been reported to occur at early time
points in studies and only a single time point measurement may not reflect the alterations
in bone metabolism that had occurred as indicated by the structural and biomechanical
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analyses. The mRNA levels of indicators of osteoblast and osteoclast activity and
signaling did not show any differences among treatment groups (Appendix A). Therefore,
we fail to accept Hypothesis 2.
Hypothesis 3: Dried plum polyphenols will decrease osteoclast differentiation and
activity under inflammatory and oxidative stress conditions.
Dried plum polyphenol extract suppressed (p<0.001) the LPS- or H2O2-induced
osteoclast differentiation and osteoclast activity as indicated by TRAP positive cell
number and resorption pit assays. Furthermore, the polyphenols also down-regulated
osteoclast differentiation and activity under normal conditions (i.e. no LPS or H2O2).
Based on the suppression of both osteoclast differentiation and activity, we accept
Hypothesis 3.
Hypothesis 4: Dried plum polyphenols will decrease the production of
inflammatory mediators by murine macrophages and osteoclasts induced by
inflammation and oxidation.
Dried plum polyphenols dose-dependently decreased (p<0.001) the LPS-induced
NO production by macrophages by as much as 78%. The polyphenol extract also
suppressed H2O2-induced TNF- production in macrophages over time, but exacerbated
LPS-induced TNF- production. LPS up-regulated COX-2 and iNOS which was
attenuated by the two lower doses of dried plum polyphenols (10 and 20 µg/ml) at 6 and
16 hrs, and was blocked by the high dose at 16 hrs. During osteoclastogenesis, dried plum
polyphenol extract dose-dependently decreased (p<0.001) the LPS-induced NO and TNF-
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 production. These findings indicate that dried plum polyphenols have the ability to
down-regulate inflammatory mediators which influence osteoclastogenesis. Although
dried plum polyphenols effectively reduced the production of inflammatory mediators
during osteoclastogenesis, they increased TNF- production by macrophages and
therefore we fail to accept Hypothesis 4.
Hypothesis 5: Dried plum polyphenols will up-regulate ALP activity and
mineralized nodule formation in osteoblast cells under both normal and inflammatory
conditions.
Dried plum polyphenols at doses of 5, 10, 20 µg/ml significantly increased the
intracellular ALP activity in MC3T3-E1 cells under normal conditions. TNF- produced
a significant reduction in intra- and extra-cellular ALP activity over time. This decrease
in ALP activity was restored by all doses of dried plum polyphenols. The TNF--induced
decrease of ALP activity was completely prevented (p<0.001) by all doses of dried plum
polyphenols at 14 days and the level of restoration in ALP activity was comparable to the
controls. Under normal conditions, 5 µg/ml and 10 µg/ml dose of dried plum polyphenols
significantly increased mineralized nodule formation. TNF- decreased (p< 0.01) the
mineralized nodule formation as indicated by the decrease of AR-S staining density and
number of mineralized nodule. TNF- induced a decrease in mineralized nodule
formation, which was restored by the all doses of polyphenols. The restoration by the 10
µg/ml dose was comparable to the control. These results suggest that increased ALP by
dried plum polyphenols led to an increase of mineralized nodule formation. Based on
these findings, Hypothesis 5 is accepted.
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Hypothesis 6: Dried plum polyphenols will increase the gene expression of
Runx2, Osterix and IGF-I under normal and inflammatory conditions.
After 48 hrs of exposure, dried plum polyphenol extracts did not significantly
alter the expression of Runx2 and Osterix under normal conditions. Under inflammatory
conditions, lower doses of polyphenols (2.5 and 5 µg/ml) restored the TNF- induced
down-regulation of Runx2 expression to the level of the control. The decrease in Osterix
expression resulting from TNF- was reversed by the 2.5 and 5 µg/ml of polyphenols to
the level of controls. In addition to transcription factors, the expression of IGF-I was
increased up to 63% with the 2.5, 5 and 10 µg/ml doses of dried plum polyphenols under
normal conditions. The highest dose (20 µg/ml) of dried plum polyphenols was the only
dose that significantly enhanced IGF-I expression under inflammatory conditions. These
alterations in gene expression were observed after only 48 hours of exposure to the
polyphenols and may or may not represent the long-term effects. Although dried plum
polyphenols were able to restore osteoblast expression of key transcription factors and
growth that were down-regulated by TNF-, in the absence of inflammation few
alterations occurred. Based on these results, we fail to accept Hypothesis 6.
Hypothesis 7: Dried plum polyphenols will decrease the RANKL expression
without altering the expression of OPG under normal and inflammatory conditions.
Under normal conditions, only the 2.5 µg/ml dose of dried plum polyphenols
significantly down-regulated the expression of RANKL and no alterations in OPG
expression were detected. In the presence of TNF-, 5, 10 and 20 µg/ml, dried plum
polyphenols significantly suppressed the TNF- induced up-regulation of RANKL
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expression by 50% (Figure 7B) with no effect on OPG. These results indicate that dried
plum polyphenol attenuated TNF- induced inflammatory signaling in MC3T3 cells.
Based on these findings, Hypothesis 7 is accepted.
Recommendations
We have shown that dietary supplementation with dried plum restored BMD in
osteopenic ORX rats at 12 months of age to the level of 9-month old sham-operated rats.
Previously, Wang and colleagues reported that after 9 months of age most indices of bone
mass and structure decline in SD males rats (Wang et al., 2001). These data suggest the
dried plum increased whole body BMD to that of peak bone mass in SD rats.
Additionally, in Study 1 bone formation and resorption markers and the gene expression
data provided relatively little information related to the alterations in bone metabolism
that occurred in response to either dried plum or PTH at 90 days. As previously indicated,
caution is needed when interpreting biochemical marker data at a single time point,
especially 90 days after the initiation of treatment in mature adult animals. For example,
the effects of treatments such as PTH on bone formation markers have been reported to
occur at early time points which may explain the lack a detectable change in bone
formation markers (serum and cellular) in the current study. Future studies should be
designed to compare to the influence of dried plum on bone metabolism to that of PTH
over time. Such studies are likely to provide more insight in the influence of dried plum
on bone metabolism.
Aside from anabolic effects of dried plum observed in Study 1, polyphenols
extracted from dried plum demonstrated the ability to increase osteoblast activity and
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inhibit osteoclast differentiation under normal conditions. These findings suggest that
dried plum is capable of improving osteoblast activity and inhibiting osteoclast activity
and differentiation independent of exogenous inflammatory conditions. Additional
studies are needed to further investigate the specific mechanisms by which dried plum’s
polyphenols increase osteoblast activity and/or inhibit osteoclastogenesis and osteoclast
activity, including key signaling molecules and other transcription factors associated with
osteoblast and osteoclast differentiation as well as the interaction between osteoblasts and
osteoclasts utilizing co-culture systems.
Although the dried plum polyphenol extract effectively suppressed osteoclast
differentiation and enhanced osteoblast activity in the in vitro studies, this extract also
contained carbohydrates and other nutritive or non-nutritive components, and does not
represent a purified mix of the polyphenols found in plums. Having raised this issue, the
polyphenol extract utilized in these studies down-regulated inflammatory mediators,
decreased osteoclast differentiation and increased osteoblast activity which is similar to
the effects of other phenolic compounds reported in the literatures (Chen et al., 2001;
Mizutani et al., 1998; Wattel et al., 2003). Though a number of polyphenolic compounds
have been shown to have positive effects on osteoclasts or osteoblasts, their ability to
prevent bone loss and most importantly restore bone in physiological conditions (animal
models or clinical studies), as shown by dried plum, appears to be somewhat novel.
These effects observed on the cellular activity and bone histomorphometry under
physiological conditions appear to be unique to dried plum.
It is unclear at this point whether the effects on osteoclasts and osteoblasts
reported here are the results of an individual phenolic compound or the action of the
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polyphenols as a whole. Additionally, the question remains as to whether there are
differences in the potency of these compounds. Studies using the available synthetic
versions of the phenolic compound in dried plum or proportionate formulations of those
found in the fruit are underway and may provide the opportunity to clarify the effects of
the polyphenols on osteoclasts and osteoblasts and to address whether the effects reported
here are the results of individual compounds or the action of the polyphenols as a whole.
However, not all of the polyphenols found in dried plum, including neochlorogenic, are
available synthetically and so some limitations exist in these experiments as well.
The results of this study provide further insight into the key mechanisms by which
dried plum enhances bone mass and microarchitecture. Based on the findings from these
studies it appears that dried plum and its polyphenols have the ability to inhibit osteoclast
differentiation and increase osteoblast activity in conjunction with attenuating
inflammatory mediators. In spite of these promising results, in vivo and in vitro studies
conducted separately may leave some uncertainty as to the effects of dried plum or its
polyphenols on bone formation and bone resorption. Further studies are warranted that
include the simultaneous evaluation of cellular activity and structural changes using
dynamic bone histomorphometry under unique physiological condition. These studies
will provide the opportunity to further understand dried plum’s mechanism of action and
whether it mimics the actions of current anti-resorptive and anabolic therapies or provides
a novel mechanism for future consideration.
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APPENDIX A
SUPPLEMENTAL MATERIALS FOR CHAPTER III
Table 1. Diet composition (g/kg diet) for the control (AIN-93) and dried plum diet
Figure 1. Bone mRNA expression of A) ALP, B) TRAP, C) COL-I, D) IGF-I, E) Runx2,
F) RANKL, and G) OPG following 90 days of consumption of control diet (ORX-
Control), dried plum (ORX-DP) or parathyroid hormone (ORX-PTH). Values were
normalized to the expression of GAPDH. Bars represent the mean ± SE for each
treatment group. Bars that share the same superscript letter are not significantly (p <0.05)
different from each other (n=3-6/group).
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Table 1. Diet composition (g/kg diet) for the control (AIN-93) and dried plum diets
Ingredients Control
(g/kg diet)
Dried plum
(g/kg diet)
Carbohydrate
Total 720.7 720.7
Cornstarch 465.7 265.7
Maltodextrin 155.0 155.0
Sucrose 100.0 100.0
Dried plum --- 250.0
Protein
Total 140.0 140.0
Casein 140.0 132.5
Dried plum --- 7.5
Fat
Total 40.0 40.0
Soybean Oil 40.0 38.75
Dried plum --- 1.25
Fiber
Total 50.0 50.0
Cellulose 50.0 27.5
Dried plum --- 22.5
Vitamin Mix 10.0 10.0
Mineral Mix
Total 35.0 35.0
Mineral mix (Ca-P deficient) 13.4 13.4
Ca carbonate 9.88 9.43
Ca from dried plum --- 0.18
K phosphate 5.6 5.0
Na phosphate 3.44 2.84
P from dried plum --- 0.27
K citrate 0.9 0.9
Sucrose 1.78 2.98
L-cystein 1.8 1.8
Caloric density (kJ/g diet) 17.6 17.4
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APPENDIX B
SUPPLEMENTAL MATERIALS FOR CHAPTER V
Figure 1. Effect of dried plum polyphenols on mineralized nodule formation at 18 days
Dried plum polyphenols increase mineralized nodule formation as indicated by Alizarin
red S staining (red color) density and number of mineralized nodule under inflammatory
and normal conditions. Cells were plated at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10 or
20 µg/ml of dried plum polyphenol extracts alone or stimulated with TNF- (1 ng/ml) for
18 days. Bars that share the same letters are not significantly different from each other.
Figure 2. Microscopic view of mineralized nodules in MC3T3 cells
Dried plum polyphenols increase mineralized nodule formation as indicated by number
and size of mineralized nodule under normal (A) and inflammatory (B) conditions. Cells
were plated at 1 × 105 cells/ml, treated with 0, 2.5, 5, 10 or 20 µg/ml of dried plum
polyphenol extracts alone or stimulated with TNF- (1 ng/ml) for 28 days. Mineralized
nodules were photogaphed under the bright field microscope.
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Figure 1. Nodule formation at 18days
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Figure 2. Microscopic view of mineralized nodules at 28days
A)
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Scope and Method of Study: The purpose of this study was to utilize the combination of
in vivo and in vitro studies to investigate the effects of dried plum (DP) on bone and
bone cell activity under conditions of elevated pro-inflammatory mediators. In Study
1, 9-month-old male osteopenic orchidectomized rats were randomly assigned to
control (AIN-93M) or DP diet (25%, w/w) for 90 days. The positive control group
consumed the control diet and received PTH (80µg/kg). In Study 2, macrophages
(RAW 264.7) were pretreated with the polyphenols extracted from DP (0, 10, 20, or
30 µg/ml) cultured with or without RANKL and then stimulated with either LPS or
hydrogen peroxide (H2O2). TRAP-positive osteoclasts and resorption pit formation
were evaluated and inflammatory mediators such as NO and TNF- by macrophages
and during their differentiation into osteoclasts were assessed. In Study 3, MC3T3-E1
cells, murine pre-osteoblasts, were utilized to determine how DP polyphenols
influence osteoblast activity, function and signaling under normal and inflammatory
conditions. Cells were pretreated with polyphenols (0, 2.5, 5, 10 and 20 µg/ml) prior
to stimulation with TNF- (0 or 1.0 ng/ml). ALP activity and mineralized nodule
formation were measured and alterations in gene expression of RANKL, OPG,
Runx2, Osterix and IGF-I were analyzed.
Findings and Conclusions: Study 1 showed that dietary supplementation with DP
restored the ORX-induced loss of bone mass and deterioration of bone structure. The
restoration of bone microarchitecture by dried plum was comparable to PTH. Study 2
revealed that DP polyphenols inhibit osteoclastogenesis and osteoclast activity which
may be mediated by the down-regulation of cytokines such as TNF- and NO. Study
3 showed that DP polyphenols enhance osteoblast activity and mineralized nodule
formation under normal and inflammatory conditions. Results in vitro studies suggest
that dried plum which has ability to down-regulate inflammatory mediators, has
potent effects on osteoclast and osteoblast activity and provide possible mechanisms
by which dried plum preserves bone mass and microarchitecture as reported in
current and previous in vivo studies.
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